GSK plc 6-K, filed Feb 4, 2026
GSK plc (GSK)
6-K
2026-02-04
For: 2026-02-04
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on February 4, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
|
|
|
GSK delivers strong 2025 performance
and re-affirms long-term outlooks
|
|
|
|
|
Sales, profit and earnings growth driven by strong Specialty
Medicines performance
|
|
|
●
|
Total
2025 sales £32.7 billion +4% AER; +7% CER
|
|
●
|
Specialty
Medicines sales £13.5 billion (+17%); Respiratory, Immunology
& Inflammation £3.8 billion (+18%); Oncology £2.0
billion (+43%); HIV sales £7.7 billion (+11%)
|
|
●
|
Vaccines
sales £9.2 billion (+2%); Shingrix £3.6 billion (+8%);
Meningitis vaccines £1.6 billion (+12%); and Arexvy £0.6 billion
(+2%)
|
|
●
|
General
Medicines sales £10.0 billion (-1%); Trelegy £3.0 billion
(+13%)
|
|
●
|
Total
operating profit >100% and Total EPS >100% driven by lower
Significant legal expenses, lower CCL charges and higher other
operating income, partly offset by intangible asset
impairments
|
|
●
|
Core
operating profit +11% and Core EPS +12% reflecting Specialty
Medicines and Vaccines growth, SG&A productivity, higher
royalty income and disciplined increased investment in R&D
portfolio progression in Oncology and Vaccines
|
|
●
|
Cash
generated from operations of £8.9 billion with free cash flow
of £4.0 billion
|
|
(Financial Performance – 2025 results unless otherwise
stated, growth % and commentary at CER as defined on page 53. In
2025 and Q4 2025, the adverse currency impact on AER versus CER
primarily reflected the strengthening of Sterling against the USD.
See page 11 for further details.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||||||
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
Turnover
|
32,667
|
|
4
|
|
7
|
|
8,618
|
|
6
|
|
8
|
|
Total
operating profit
|
7,932
|
|
97
|
|
>100
|
|
1,100
|
|
58
|
|
65
|
|
Total
operating margin %
|
24.3%
|
|
11.5ppts
|
|
11.9ppts
|
|
12.8%
|
|
4.2ppts
|
|
4.6ppts
|
|
Total
EPS
|
141.1p
|
|
>100
|
|
>100
|
|
15.8p
|
|
56
|
|
65
|
|
Core
operating profit
|
9,783
|
|
7
|
|
11
|
|
1,634
|
|
14
|
|
18
|
|
Core
operating margin %
|
29.9%
|
|
0.7ppts
|
|
1.1ppts
|
|
19.0%
|
|
1.4ppts
|
|
1.6ppts
|
|
Core
EPS
|
172.0p
|
|
8
|
|
12
|
|
25.5p
|
|
10
|
|
14
|
|
Cash
generated from operations
|
8,943
|
|
14
|
|
|
|
2,689
|
|
4
|
|
|
|
|
|
|
R&D momentum further strengthens growth prospects:
|
|
|
Strong pipeline progress in 2025:
|
|
|
●
|
5 major
FDA approvals: Blenrep,
Exdensur, Nucala COPD, Penmenvy, Blujepa
|
|
●
|
7
pivotal trial starts including: risvutatug rezetecan (ris-rez) for
2L/3L ES-SCLC; efimosfermin in MASH; Exdensur for COPD; and velzatinib for
2L GIST
|
|
RI&I and Oncology pipelines strengthened:
|
|
|
●
|
New
assets acquired: efimosfermin (liver disease); velzatinib/IDRX-42
(gastrointestinal cancer); and agreement to acquire ozureprubart
(food allergies)
|
|
●
|
Agreements/collaborations
with Hengrui (RI&I and oncology); Empirico (COPD); and LTZ
Therapeutics (oncology)
|
|
●
|
29
projects currently in clinical development for RI&I and
Oncology diseases
|
|
Further pipeline acceleration expected in 2026:
|
|
|
●
|
2 new
major product approvals expected: bepirovirsen, potential
first-in-class treatment for chronic hepatitis B; and tebipenem,
first oral treatment for complicated UTIs
|
|
●
|
5
pivotal readouts: bepirovirsen for chronic hepatitis B (positive);
camlipixant (chronic cough); Jemperli (rectal cancer);
Q4M HIV
PrEP; and Exdensur for
EGPA
|
|
●
|
10
pivotal trial starts, including for ADCs B7-H3 (ris-rez) &
B7-H4 (mocertatug rezetecan, mo-rez) to treat multiple cancer
types
|
|
Continued commitment to shareholder returns
|
|
|
●
|
Q4 2025
dividend of 18p declared; 66p FY 2025; 70p expected for full year
2026
|
|
●
|
£1.4
billion executed to date as part of the £2 billion share
buyback programme announced at FY 2024
|
|
2026 guidance and 2031 sales outlook reaffirmed
|
|
|
●
|
Expect
2026 turnover growth of between 3% to 5%; Core operating profit
growth of between 7% to 9%; Core EPS growth of between 7% to
9%
|
|
●
|
2031
sales outlook of more than £40 billion
|
Guidance all at CER
|
|
|
Luke Miels, Chief Executive Officer, GSK:
“GSK
delivered another strong performance in 2025, driven mainly by
Specialty Medicines, with double-digit sales growth in Respiratory,
Immunology & Inflammation (RI&I), Oncology and HIV. Good
R&D progress also continued, with 5 major product approvals
achieved and several acquisitions and new partnerships completed to
strengthen the pipeline further in oncology and RI&I. We expect
this positive momentum to continue in 2026, which will be a key
year of execution and operational delivery with strong focus on
commercial launches and accelerating R&D. We are well placed to
move forward in this next phase for GSK - to deliver our outlooks -
and to create new value for patients and
shareholders.”
|
The Total results are presented in summary above and on page 8 and
Core results reconciliations are presented on pages 20-21 and
23-24. Core results are a non-IFRS measure that may be considered
in addition to, but not as a substitute for, or superior to,
information presented in accordance with IFRS. The following terms
are defined on pages 53-54: Core results, AER% growth, CER% growth
and other non-IFRS measures. GSK provides guidance on a Core
results basis only for the reasons set out on page 18. All
expectations, guidance and targets regarding future performance and
dividend payments should be read together with ‘Guidance and
outlooks, assumptions and cautionary statements’ on page
55-56. Abbreviations are defined on page 57.
2026 Guidance
GSK
provides its full-year 2026 guidance at constant exchange rates
(CER).
|
|
|
Turnover is expected to
increase between 3 to 5 per cent
|
|
Core operating profit is
expected to increase between 7 to 9 per cent
|
|
Core earnings per share is expected to increase between 7 to 9 per
cent
|
This
guidance is supported by the following turnover expectations for
full-year 2026 at CER
|
|
|
|
|
Specialty Medicines
|
–
|
expected
increase of a low double-digit per
cent in turnover
|
|
Vaccines
|
–
|
expected
decline of a low single-digit per
cent to stable in turnover
|
|
General Medicines
|
–
|
expected
decline of a low single-digit per
cent to stable in turnover
|
Core
operating profit is expected to grow between 7 to 9 per cent at
CER. GSK expects to deliver leverage at a gross margin level due to
improved product mix from Specialty Medicines growth and continued
operational efficiencies. In addition, GSK anticipates further
leverage in Operating profit as we continue to take a returns-based
approach to SG&A investments, with SG&A expected to grow at
a low single-digit percentage. Royalty income is now expected to be
at £800-850 million. R&D is expected to grow ahead of
sales as we continue to invest in the pipeline while driving
operational efficiencies.
Core
earnings per share is also expected to increase between 7 to 9 per
cent at CER, in line with Core operating profit growth, reflecting
higher interest charges and the tax rate which is expected to rise
to around 17.5%, offset by the expected benefit from the share
buyback programme. Expectations for non-controlling interests
remain unchanged relative to 2025.
Agreement with US Government to lower the cost of prescription
medicines for American patients
As
previously announced, on 19 December 2025 GSK entered into an
agreement with the US Administration to lower the cost of
prescription medicines for American patients. The agreement entered
into covers both GSK and ViiV Healthcare and, assuming expected
implementation, excludes both companies from s232 tariffs for 3
years. Detailed terms of the agreement remain confidential. Our
full year guidance is inclusive of the expected impact of the
agreement.
Dividend policy
GSK has
declared an increased dividend for Q4 2025 of 18p per share and 66p
per share for the full year 2025, reflecting strong business
performance during 2025 and consistent with the Dividend policy and
the expected pay-out ratio which remain unchanged. The expected
dividend for 2026 is 70p per share. GSK's future dividend policy
and guidance regarding the expected dividend pay-out in 2026 are
provided on page 37.
GSK
commenced a £2 billion share buyback programme in Q1 2025, to
be implemented over the period to the end of Q2 2026.
Exchange rates
If
exchange rates were to hold at the closing rates on 28 January 2026
($1.38/£1, €1.15/£1 and Yen 210/£1) for the
rest of 2026, the estimated impact on 2026 Sterling turnover growth
for GSK would be -3% and if exchange gains or losses were
recognised at the same level as in 2025, the estimated impact on
2026 Sterling Core Operating Profit growth for GSK would be
-6%.
Results presentation
A
conference call and webcast for investors and analysts of the
quarterly results will be hosted by Luke Miels, CEO, at 11.00 am
GMT (US EST at 06.00 am) on 4 February 2026. Presentation
materials will be published on www.gsk.com prior to the webcast and
a transcript of the webcast will be published
subsequently.
Notwithstanding
the inclusion of weblinks, information available on the
company’s website, or from non GSK sources, is not
incorporated by reference into this Results
Announcement.
|
|
|
Performance:
turnover
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
2025
|
|
Q4 2025
|
||||||||
|
|
£m
|
|
Growth
AER%
|
|
Growth
CER%
|
|
£m
|
|
Growth
AER%
|
|
Growth
CER%
|
|
HIV
|
7,687
|
|
8
|
|
11
|
|
2,149
|
|
9
|
|
11
|
|
Respiratory,
Immunology & Inflammation
|
3,810
|
|
15
|
|
18
|
|
1,089
|
|
18
|
|
21
|
|
Oncology
|
1,977
|
|
40
|
|
43
|
|
567
|
|
39
|
|
42
|
|
Specialty Medicines
|
13,474
|
|
14
|
|
17
|
|
3,805
|
|
15
|
|
18
|
|
Shingles
|
3,558
|
|
6
|
|
8
|
|
1,008
|
|
19
|
|
20
|
|
Meningitis
|
1,583
|
|
10
|
|
12
|
|
313
|
|
6
|
|
6
|
|
RSV
(Arexvy)
|
593
|
|
1
|
|
2
|
|
198
|
|
25
|
|
25
|
|
Influenza
|
303
|
|
(26)
|
|
(24)
|
|
80
|
|
(24)
|
|
(21)
|
|
Established
Vaccines
|
3,120
|
|
(7)
|
|
(5)
|
|
694
|
|
(14)
|
|
(13)
|
|
Vaccines
|
9,157
|
|
–
|
|
2
|
|
2,293
|
|
4
|
|
4
|
|
Respiratory
|
7,068
|
|
(2)
|
|
–
|
|
1,785
|
|
(1)
|
|
1
|
|
Other
General Medicines
|
2,968
|
|
(8)
|
|
(4)
|
|
735
|
|
(8)
|
|
(6)
|
|
General Medicines
|
10,036
|
|
(4)
|
|
(1)
|
|
2,520
|
|
(3)
|
|
(1)
|
|
Total
|
32,667
|
|
4
|
|
7
|
|
8,618
|
|
6
|
|
8
|
|
By Region:
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
16,859
|
|
3
|
|
6
|
|
4,443
|
|
3
|
|
7
|
|
Europe
|
7,533
|
|
13
|
|
12
|
|
2,067
|
|
18
|
|
13
|
|
International
|
8,275
|
|
(1)
|
|
4
|
|
2,108
|
|
4
|
|
7
|
|
Total
|
32,667
|
|
4
|
|
7
|
|
8,618
|
|
6
|
|
8
|
|
|
|
Financial Performance – 2025 and Q4 2025 results unless
otherwise stated, growth % and commentary at CER. In 2025 and Q4
2025, the adverse currency impact on AER versus CER primarily
reflected the strengthening of Sterling against the USD. See page
11 for further details.
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Specialty Medicines
|
13,474
|
14%
|
17%
|
|
3,805
|
15%
|
18%
|
Specialty Medicines sales grew by double-digit percentages in the
full year and quarter, reflecting continued growth across disease
areas, with strong performances in HIV, Respiratory, Immunology
& Inflammation, and Oncology.
|
|
|
|
|
|
|
|
|
|
HIV
|
7,687
|
8%
|
11%
|
|
2,149
|
9%
|
11%
|
HIV
sales grew 11% for the full year, driven by strong patient demand
growth of +10ppts with Dovato, Cabenuva and Apretude more than offsetting the
decline in Triumeq
following guideline changes at the end of 2024. Full year growth
also benefitted from continued favourable pricing due to channel
mix in the US, which offset the impact of the IRA Medicare Part D
redesign and pricing pressures across the other regions.
Long-acting Medicines contributed over 75% of total HIV growth in
2025 with Cabenuva
contributing 55%.
Quarterly
growth was 11%, driven by strong patient demand growth of +9ppts
and continued favourable pricing from channel mix, which offset the
impact of the IRA Medicare Part D redesign. The US maintained
strong double-digit growth with 15% for the quarter.
|
|
|
|
|
|
|
|
|
|
Oral
2DR
|
3,334
|
14%
|
16%
|
|
941
|
14%
|
16%
|
Dovato, the first and only once-daily oral 2DR for the
treatment of HIV infection in both treatment naive and virally
suppressed adults and adolescents, continues to be the largest
product in the HIV portfolio with sales of £2,678 million in
2025 and growing 22% versus 2024.
|
|
|
|
|
|
|
|
|
|
Long-Acting
|
1,841
|
42%
|
46%
|
|
539
|
37%
|
41%
|
Cabenuva, the only complete long-acting injectable regimen
for HIV treatment, reached sales of £1,402 million in 2025,
growing 42% due to strong patient demand across US and Europe.
Apretude, the first
long-acting injectable option for HIV prevention, delivered sales
of £439 million in 2025, growing 62% compared to 2024. In the
US, long-acting injectables now account for 30% of total HIV
sales.
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Respiratory,
Immunology & Inflammation
|
3,810
|
15%
|
18%
|
|
1,089
|
18%
|
21%
|
Sales
grew at a double-digit rate in the full year and in the quarter,
and were primarily comprised of contributions from Nucala in respiratory and Benlysta in immunology.
|
|
|
|
|
|
|
|
|
|
Nucala
|
2,008
|
13%
|
15%
|
|
567
|
17%
|
19%
|
Nucala is an IL-5 antagonist monoclonal antibody treatment
for severe asthma, with additional indications including CRSwNP,
EGPA, HES and COPD. Sales growth was driven by strong global
performance, with double-digit growth across all regions in the
full year and quarter reflecting higher patient demand for
treatments addressing eosinophilic-led disease. US double-digit
growth in the full year accelerated in the quarter following the
recent launch in COPD, with increases in volume from higher patient
uptake partially offset by ongoing pricing pressures including the
impact of IRA Medicare Part D redesign.
|
|
|
|
|
|
|
|
|
|
Benlysta
|
1,773
|
19%
|
22%
|
|
516
|
22%
|
26%
|
Sales
of Benlysta, a monoclonal
antibody treatment for lupus, grew in the full year and quarter
representing strong demand and volume growth with bio-penetration
rates having increased across many markets.
|
|
|
|
|
|
|
|
|
|
Oncology
|
1,977
|
40%
|
43%
|
|
567
|
39%
|
42%
|
Oncology
sales are largely comprised of sales from Jemperli, Zejula and Ojjaara/Omjjara. Strong Oncology sales
growth in the full year and quarter were largely driven by
increasing patient demand for Jemperli and Ojjaara/Omjjara, partially offset by
decreases in Zejula.
Blenrep, a treatment in
relapsed/refractory multiple myeloma, achieved sales in 2025 of
£17 million following launch in the UK in Q2 2025, US in Q4
2025 and from further initial commercial introductions in some
smaller markets during H2 2025.
|
|
|
|
|
|
|
|
|
|
Jemperli
|
861
|
84%
|
89%
|
|
261
|
75%
|
79%
|
Sales
of Jemperli grew strongly
in the full year and quarter, driven largely by continued volume
growth following Q3 2024 FDA approval and Q1 2025 EMA approval
expanding the indication to include all adult patients with primary
advanced or recurrent endometrial cancer. Strong growth continues
in the US from high patient uptake, with the Europe and
International regions increasingly contributing to sales and
growth, with Jemperli now
available in over 39 countries worldwide.
|
|
|
|
|
|
|
|
|
|
Zejula
|
557
|
(6%)
|
(4%)
|
|
138
|
(3%)
|
(3%)
|
Sales
of Zejula, a PARP inhibitor
treatment for ovarian cancer, reduced in the full year and quarter.
In the US, sales decreased in the full year driven by ongoing
volume reductions, including impacts of an FDA labelling update
restricting use to certain patient populations, and unfavourable
pricing including the impacts of IRA Medicare Part D redesign. In
the quarter, the US grew single digit as these impacts were more
than offset by favourable channel mix pricing adjustments. The
Europe and International regions continued to decline in the full
year largely driven by reduced volumes from increased competition.
In the quarter, Europe declined whilst International was broadly
stable.
|
|
|
|
|
|
|
|
|
|
Ojjaara/Omjjara
|
554
|
57%
|
60%
|
|
158
|
34%
|
37%
|
Sales
of Ojjaara/Omjjara, a
treatment for myelofibrosis patients with anaemia, grew strongly in
the full year and quarter. US sales growth was driven by volume
with continued increases in patient uptake. Sales and growth
contributions from Europe and International continued to increase
following high patient uptake, and from commercial launches in 2025
across the regions including in France, Spain Italy, Australia and
Canada. Ojjaara/Omjjara is
now available in over 30 countries worldwide.
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Vaccines
|
9,157
|
–%
|
2%
|
|
2,293
|
4%
|
4%
|
Vaccines sales increased in both the year and quarter driven by
strong ex-US demand for Shingrix, Arexvy and Meningitis vaccines, partly offset by lower US
demand for Shingrix, Arexvy and Influenza vaccines together with lower
International sales of Established vaccines. Growth in the quarter
also benefitted from higher Shingrix sales in China.
|
|
|
|
|
|
|
|
|
|
Shingles
|
3,558
|
6%
|
8%
|
|
1,008
|
19%
|
20%
|
Shingrix had another record year, in which sales grew
strongly in both the year and quarter reflecting double-digit
growth in Europe and International driven by significant increased
demand, partly offset by lower sales in the US.
In
Europe, Shingrix sales grew
at 42% for the year and quarter driven by continuous strong uptake
from the launch in France together with higher market demand and
expanded public funding across several countries.
Sales
of Shingrix in
International increased by 13% for the year reflecting accelerated
demand in Japan following expanded reimbursement from April 2025
together with continued uptake across several countries, partially
offset by a strong 2024 comparator including rapid uptake from the
national immunisation programme (NIP) in Australia. Q4 2025 sales
growth also benefitted from higher sales to our co-promotion
partner in China versus a low 2024 comparator.
US
sales decreased by 17% in the year and quarter due to the
continuing slowdown in the pace of penetration of
harder-to-activate unvaccinated consumers. The US cumulative
immunisation rate reached 44%, up 4 percentage points compared to
12 months earlier(1).
Shingrix is now launched in 61 countries, 29 of those with
public funding, with markets outside the US representing 66% of
2025 global sales (2024: 56%). The overwhelming majority of ex-US
Shingrix opportunity is
concentrated in 10 markets where the average immunisation rate is
around 10% with significantly higher uptake in funded
cohorts.
|
|
|
|
|
|
|
|
|
|
Meningitis
|
1,583
|
10%
|
12%
|
|
313
|
6%
|
6%
|
Strong
double-digit growth of Meningitis vaccines in the year was led by
Bexsero, a vaccine against
meningitis B and also included initial sales from the US launch of
Penmenvy, a pentavalent
vaccine against meningitis A, B, C, W and Y. Bexsero grew in Europe driven by
continued uptake following recommendation and reimbursement in
Germany together with expanded cohort recommendations in France.
Sales also grew in International due to higher demand and
geographic expansion.
|
|
|
|
|
|
|
|
|
|
RSV
|
593
|
1%
|
2%
|
|
198
|
25%
|
25%
|
Arexvy sales growth was driven by Europe and International
related to recommendation and reimbursement in Germany and tender
deliveries in Spain and Canada. While Arexvy maintained US market leading
share in the older adult setting in 2025, sales declined reflecting
slower market uptake impacted by a harder-to-activate patient
cohort and lower market share partly offset by favourable returns
provision adjustments. Q4 2025 global sales growth was positively
impacted by increasing uptake momentum in Germany. Arexvy is approved in 69 markets
globally, 21 countries have national RSV vaccination
recommendations for older adults and 9, including the US, have
reimbursement programmes for Arexvy in place at the year
end.
|
|
|
|
|
|
|
|
|
|
Influenza
|
303
|
(26%)
|
(24%)
|
|
80
|
(24%)
|
(21%)
|
Influenza
vaccines sales declined mainly in the US driven by competitive
pressure.
|
|
|
|
|
|
|
|
|
|
Established
Vaccines
|
3,120
|
(7%)
|
(5%)
|
|
694
|
(14%)
|
(13%)
|
Established
Vaccines sales decreased in the full year as a result of the impact
of divested brands, competitive pressure for Synflorix and Cervarix and lower US demand and
unfavourable pricing for Hepatitis vaccines. This was partly offset
by higher sales of measles, mumps, rubella and varicella (MMRV)
vaccines, including a one-off Q3 2025 sale of bulk antigen together
with favourable US CDC stockpile movements for Infanrix/Pediarix. The decline in the
quarter was also driven by the timing of deliveries of Synflorix and lower sales of
Rotarix.
(1) Based on data from IQVIA up until the end of Q3
2025
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
General Medicines
|
10,036
|
(4%)
|
(1%)
|
|
2,520
|
(3%)
|
(1%)
|
Sales include contributions from both the Respiratory portfolio,
including Trelegy, and the Other General Medicine portfolio. Sales
were broadly stable in the full year and the quarter, with growth
in Trelegy offset by reductions in other respiratory and
Other General Medicine product sales.
|
|
|
|
|
|
|
|
|
|
Respiratory
|
7,068
|
(2%)
|
–%
|
|
1,785
|
(1%)
|
1%
|
Sales
were broadly stable in the full year and quarter, with growth in
Trelegy offset by decreases
in other respiratory products. Other respiratory products continue
to reduce across all regions as a result of continued generic
erosion and competitive pressures.
|
|
|
|
|
|
|
|
|
|
Trelegy
|
2,986
|
11%
|
13%
|
|
740
|
11%
|
14%
|
Trelegy sales continued to grow in the full year and
quarter, with continued strong volume growth across all regions
reflecting patient demand, SITT class growth, and increased market
share. In the US, sales exceeded £2 billion for the full year
and grew double-digit, with continued strong volume growth
partially offset by unfavourable pricing resulting from channel mix
and pricing pressures, including the impact of IRA Medicare Part D
redesign.
|
|
|
|
|
|
|
|
|
|
Other
General Medicines
|
2,968
|
(8%)
|
(4%)
|
|
735
|
(8%)
|
(6%)
|
Other
General Medicines sales decreased in the full year and quarter,
reflecting the impacts of generic competition across the
portfolio.
By Region
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
US
|
16,859
|
3%
|
6%
|
|
4,443
|
3%
|
7%
|
US
performance in the full year and quarter reflected the introduction
of the IRA Medicare Part D redesign, which adversely impacted a
number of products across Specialty Medicines, Vaccines and General
Medicines.
Specialty
Medicines double-digit sales growth in the full year and quarter
was driven by strong double-digit growth in Oncology, HIV and
Benlysta, driven largely by
patient demand. Nucala also
grew double-digit in the full year and accelerated in the quarter
following the recent launch in COPD, with increases in volume from
higher patient uptake partly offset by ongoing pricing
pressures.
Vaccines
sales decreased due to lower demand for both Shingrix and Arexvy driven primarily by the
continued challenge of activating harder-to reach consumers and
competitive pressure for Influenza vaccines. Established vaccines
growth in MMRV vaccines related to outbreaks and, for Infanrix/Pediarix, to favourable CDC
stockpile replenishments which were more than offset by lower US
demand and unfavourable pricing for Hepatitis vaccines
General
Medicines sales were broadly stable in the full year and quarter.
Trelegy sales grew
double-digit in the full year and quarter driven by strong volume
increases. Growth in Trelegy was offset by reductions in
other products across the other respiratory and Other General
Medicine portfolios.
|
|
|
|
|
|
|
|
|
|
Europe
|
7,533
|
13%
|
12%
|
|
2,067
|
18%
|
13%
|
Specialty
Medicines sales grew double-digit in the full year and quarter due
to continued strong performance in Oncology, Benlysta and Nucala including the benefit from new
indication launches. HIV sales grew single-digit in the full year
and quarter driven by patient demand.
Vaccines
sales grew around 30% in both the year and quarter driven by
Shingrix launch uptake in
France together with higher market demand and expanded public
funding across several countries. Arexvy and Bexsero sales also grew strongly mainly
in Germany following recommendations and
reimbursements.
General
Medicines sales decreased in the full year and quarter, with growth
for Trelegy and
Anoro being more than
offset by decreases across other general medicine
products.
|
|
|
|
|
|
|
|
|
|
International
|
8,275
|
(1%)
|
4%
|
|
2,108
|
4%
|
7%
|
Specialty
Medicines double-digit sales growth in the full year and quarter
was driven by Nucala in
respiratory, Benlysta in
immunology, and Oncology. HIV sales grew mid single-digit in the
full year, however were broadly stable in the quarter due to the
timings of tenders.
Vaccines
sales grew in the year driven by accelerated Shingrix demand primarily in Japan,
partly offset by a strong 2024 comparator in Australia. Growth
across Shingrix, Meningitis
vaccines and Arexvy was
partly offset by lower sales of Established vaccines primarily
reflecting the impact of divested brands and lower demand. Sales in
the quarter also benefitted from higher Shingrix sales to our co-promotion
partner in China versus a low 2024 comparator.
General Medicines sales were broadly stable in the full year and
the quarter. Performance reflected double-digit growth for
Trelegy and growth in Anoro being offset by decreases across other general
medicine products.
|
|
|
Financial
performance
|
|
|
|
|
|
|
|
|
|
|
Total Results
|
2025
|
|
Q4 2025
|
||||
|
|
£m
|
%
AER
|
%
CER
|
|
£m
|
%
AER
|
%
CER
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
32,667
|
4
|
7
|
|
8,618
|
6
|
8
|
|
Cost of
sales
|
(9,017)
|
–
|
–
|
|
(2,657)
|
4
|
4
|
|
Selling,
general and administration
|
(9,088)
|
(17)
|
(15)
|
|
(2,639)
|
(1)
|
2
|
|
Research
and development
|
(7,525)
|
18
|
19
|
|
(2,350)
|
16
|
17
|
|
Royalty
income
|
879
|
38
|
38
|
|
245
|
39
|
39
|
|
Other
operating income/(expense)
|
16
|
|
|
|
(117)
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
7,932
|
97
|
>100
|
|
1,100
|
58
|
65
|
|
Net
finance expense
|
(532)
|
(3)
|
(2)
|
|
(149)
|
7
|
8
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
1
|
|
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
7,401
|
>100
|
>100
|
|
950
|
69
|
78
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(1,112)
|
|
|
|
(223)
|
|
|
|
Tax rate %
|
15.0%
|
|
|
|
23.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
6,289
|
>100
|
>100
|
|
727
|
45
|
53
|
|
Profit
attributable to non-controlling interests
|
573
|
|
|
|
91
|
|
|
|
Profit
attributable to shareholders
|
5,716
|
|
|
|
636
|
|
|
|
|
6,289
|
>100
|
>100
|
|
727
|
45
|
53
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share
|
141.1p
|
>100
|
>100
|
|
15.8p
|
56
|
65
|
|
Financial Performance – 2025 and Q4 2025 results unless
otherwise stated, growth % and commentary at CER. In 2025 and Q4
2025, the adverse currency impact on AER versus CER primarily
reflected the strengthening of Sterling against the USD. See page
11 for further details.
|
|||||||
|
|
|
Core results
Reconciliations
between Total results and Core results Full Year 2025, Full Year 2024, Q4 2025 and Q4 2024
are set out on pages 20, 21, 23 and 24.
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
£m
|
%
AER
|
%
CER
|
|
£m
|
%
AER
|
%
CER
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
32,667
|
4
|
7
|
|
8,618
|
6
|
8
|
|
Cost of
sales
|
(8,206)
|
4
|
5
|
|
(2,435)
|
4
|
4
|
|
Selling,
general and administration
|
(8,989)
|
–
|
3
|
|
(2,677)
|
(1)
|
2
|
|
Research
and development
|
(6,568)
|
9
|
11
|
|
(2,117)
|
16
|
18
|
|
Royalty
income
|
879
|
38
|
38
|
|
245
|
39
|
39
|
|
|
|
|
|
|
|
|
|
|
Core
operating profit
|
9,783
|
7
|
11
|
|
1,634
|
14
|
18
|
|
|
|
|
|
|
|
|
|
|
Core
profit before taxation
|
9,265
|
8
|
11
|
|
1,481
|
15
|
19
|
|
Taxation
|
(1,584)
|
8
|
12
|
|
(256)
|
47
|
52
|
|
Tax rate %
|
17.1%
|
|
|
|
17.3%
|
|
|
|
Core
profit after taxation
|
7,681
|
7
|
11
|
|
1,225
|
9
|
13
|
|
Core
profit attributable to non-controlling interests
|
712
|
|
|
|
199
|
|
|
|
Core
profit attributable to shareholders
|
6,969
|
|
|
|
1,026
|
|
|
|
|
7,681
|
7
|
11
|
|
1,225
|
9
|
13
|
|
Core
Earnings per share
|
172.0p
|
8
|
12
|
|
25.5p
|
10
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Cost of
sales
|
Total
|
9,017
|
–%
|
–%
|
|
2,657
|
4%
|
4%
|
|
% of sales
|
27.6%
|
(1.2%)
|
(1.7%)
|
|
30.8%
|
(0.7%)
|
(1.3%)
|
|
|
Core
|
8,206
|
4%
|
5%
|
|
2,435
|
4%
|
4%
|
|
|
% of sales
|
25.1%
|
–%
|
(0.4%)
|
|
28.3%
|
(0.6%)
|
(1.2%)
|
|
Total
cost of sales as a percentage of sales decreased in the full year
and quarter primarily driven by core cost of sales benefits and in
the full year from additional amortisation in Q3 2024 for
Zejula and Jemperli as well as lower major
restructuring and transaction-related items.
Core
cost of sales as a percentage of sales decreased in the full year
and quarter, with benefits from Specialty Medicines and regional
mix as well as operational efficiencies, being offset by inventory
provision movements compared to 2024. The full year also included
pricing impacts largely due to the implementation of Medicare Part
D reform as well as an adverse comparison to higher price benefits
in the comparator period. The quarter also included higher margin
Vaccines in International and supply chain charges at a similar
level to Q4 2024.
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Selling, general
& administration
|
Total
|
9,088
|
(17%)
|
(15%)
|
|
2,639
|
(1%)
|
2%
|
|
% of sales
|
27.8%
|
(7.3%)
|
(7.1%)
|
|
30.6%
|
(2.2%)
|
(1.8%)
|
|
|
Core
|
8,989
|
–%
|
3%
|
|
2,677
|
(1%)
|
2%
|
|
|
% of sales
|
27.5%
|
(1.1%)
|
(0.9%)
|
|
31.1%
|
(2.2%)
|
(1.8%)
|
|
Total
SG&A as a percentage of sales decreased in the full year driven
by lower Significant legal expenses, driven by the Q3 2024 charge
of £1.8 billion ($2.3 billion) in relation to Zantac.
Core
SG&A growth in the full year and quarter reflected continued
disciplined investment to support new asset launches, including
Blenrep, Penmenvy, Exdensur
and Blujepa, as well as
growth of key assets including Nucala, Shingrix, long-acting HIV
medicines and Ojjaara/Omjjara, as well as charges in
the quarter to drive future efficiencies. This was offset by
reallocation of spend from General Medicines and the acceleration
of ongoing productivity initiatives. Full year Core SG&A growth
also included a one percentage point impact driven by the Q1 2024
reversal of the legal provision related to the Zejula royalty dispute, following a
successful appeal.
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Research
& development
|
Total
|
7,525
|
18%
|
19%
|
|
2,350
|
16%
|
17%
|
|
% of sales
|
23.0%
|
2.6%
|
2.4%
|
|
27.3%
|
2.2%
|
2.1%
|
|
|
Core
|
6,568
|
9%
|
11%
|
|
2,117
|
16%
|
18%
|
|
|
% of sales
|
20.1%
|
0.9%
|
0.8%
|
|
24.6%
|
2.1%
|
2.0%
|
|
Total
R&D increase in the full year and quarter was driven by an
increase in Core R&D investment, as well as higher impairment
charges in the full year which included an impairment charge of
£471 million related to the termination of the belrestotug
development programme (anti-TIGIT mAb) in Q2 2025.
Core
R&D investment increased reflecting progression across the
portfolio. In Oncology, this included acceleration in work on ADCs
(B7-H3 and B7-H4) and IDRX-42, the GIST treatment acquired in Q1
2025. In Specialty Medicines, increased investment was driven by
efimosfermin acquired from Boston Pharmaceuticals in Q3 2025 and
bepirovirsen, as well as progression of ULA treatment and PrEP
programmes, notably Q4M and Q6M. Growth in the full year and
quarter was partly offset by lower spend on depemokimab following
filing in Q4 2024.
Investment
also increased on clinical trial programmes associated with the
pneumococcal MAPS and mRNA seasonal flu.
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Royalty
income
|
Total
|
879
|
38%
|
38%
|
|
245
|
39%
|
39%
|
|
|
Core
|
879
|
38%
|
38%
|
|
245
|
39%
|
39%
|
The
increase in Total and Core royalty income in the full year and Q4
2025 was primarily driven by Kesimpta(1),
Abrysvo(2)
and Comirnaty(3) royalties. The
full year included historic royalties recognised in association
with the settlement of an IP dispute.
(1) Kesimpta is manufactured by and a trademark
of Novartis AG (2) Abrysvo is manufactured by and a trademark of
Pfizer Inc. (3) Comirnaty is manufactured by and a trademark of
BioNTech and Pfizer Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Other
operating income/(expense)
|
Total
|
16
|
>100%
|
>100%
|
|
(117)
|
66%
|
66%
|
The
full year other operating income reflected a charge of £488
million (2024: £1,839 million) principally arising from the
remeasurement of CCLs and the liabilities for the Pfizer, Inc
(Pfizer) put option, primarily reflecting the net impact of
discount unwind, updated sales and milestone forecasts and foreign
currency movements. See page 22 for further details. Other net
operating income at £504m (2024: £309 million) includes
the £367 million ($500 million) settlement from CureVac as
well as fair value movements on equity investments and other net
income.
In Q4
2025 other operating income included a charge of £295 million
(Q4 2024: £417 million) arising from the remeasurement of
contingent consideration liabilities (CCL) and the liabilities for
the Pfizer put option. The charge in the current quarter primarily
reflected the net impact of updated sales forecasts, discount
unwind and exchange movements partly offset by reduced forecast
milestone payments. See page 25 for further details. Other net
operating income at £178 million (Q4 2024: £73 million)
includes £99 million ($130 million) of settlement from CureVac
as well as fair value movements on equity investments and other net
income.
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Operating
profit
|
Total
|
7,932
|
97%
|
>100%
|
|
1,100
|
58%
|
65%
|
|
|
% of sales
|
24.3%
|
11.5%
|
11.9%
|
|
12.8%
|
4.2%
|
4.6%
|
|
|
Core
|
9,783
|
7%
|
11%
|
|
1,634
|
14%
|
18%
|
|
|
% of sales
|
29.9%
|
0.7%
|
1.1%
|
|
19.0%
|
1.4%
|
1.6%
|
Total
operating profit margin was higher in the full year mainly due to
the £1.8 billion charge for the Zantac settlement in Q3 2024, partly
offset by higher impairment charges. In the quarter operating
profit margin was higher due to higher other net operating income
and lower CCL charges.
Core
operating profit growth in the full year and quarter primarily
reflected higher turnover, favourable product mix and royalty
income including from IP settlements. Growth was partly offset by
increased investment in R&D, new asset launches and growth
assets, and adverse pricing impacts, as well as in the full year
the Q1 2024 reversal of the legal provision related to the
Zejula royalty dispute,
following a successful appeal. In the quarter, productivity
programmes and supply chain charges totalled £300 million,
split evenly between cost of sales and SG&A.
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Net
finance expense
|
Total
|
532
|
(3%)
|
(2%)
|
|
149
|
7%
|
8%
|
|
|
Core
|
508
|
(5%)
|
(4%)
|
|
150
|
9%
|
10%
|
The
decrease in net finance costs in the full year was mainly driven by
favourable movements on derivatives fair value, favourable interest
on tax and higher swap interest income, partly offset by higher
interest expense on debt. Strong operating cashflows in the full
year were partly offset by finance costs associated with the share
buyback programme and Zantac settlement payments. The
increase in the quarter was mainly driven by lower interest income
on cash following Zantac
settlement payments and the share buyback programme partly offset
by favourable movements on derivatives fair value.
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Taxation
|
Total
|
1,112
|
>100%
|
>100%
|
|
223
|
>100%
|
>100%
|
|
|
Tax rate %
|
15.0%
|
|
|
|
23.5%
|
|
|
|
|
Core
|
1,584
|
8%
|
12%
|
|
256
|
47%
|
52%
|
|
|
Tax rate %
|
17.1%
|
|
|
|
17.3%
|
|
|
The
effective tax rate on Total results reflected the different tax
effects of the various Adjusting items included in Total results,
including non-taxable revaluations of contingent consideration
liabilities associated with recent acquisitions.
The
effective tax rate on Core profits was broadly in line with
expectations for the year. Issues related to taxation are described
in Note 14, ‘Taxation’ in the Annual Report 2024. The
Group continues to believe it has made adequate provision for the
liabilities likely to arise from periods that are open and not yet
agreed by relevant tax authorities. The ultimate liability for such
matters may vary from the amounts provided and is dependent upon
the outcome of agreements with relevant tax
authorities.
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Non-controlling
interests ("NCIs")
|
Total
|
573
|
52%
|
58%
|
|
91
|
5%
|
10%
|
|
Core
|
712
|
9%
|
12%
|
|
199
|
15%
|
18%
|
|
The
increase in Total and Core NCIs in the full year and quarter was
primarily driven by higher core profit allocations from ViiV
Healthcare, and in the full year a lower remeasurement loss on the
CCL compared to 2024 impacting Total NCIs.
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
|
£p
|
AER
|
CER
|
|
£p
|
AER
|
CER
|
|
Earnings
per share
|
Total
|
141.1p
|
>100%
|
>100%
|
|
15.8p
|
56%
|
65%
|
|
Core
|
172.0p
|
8%
|
12%
|
|
25.5p
|
10%
|
14%
|
|
The
increase in the full year and Q4 2025 Total EPS was primarily
driven by lower Significant legal charges, lower CCL charges and
higher other net operating income, partly offset by higher
impairment charges.
The
increase in the Core EPS in the full year and quarter primarily
reflected the growth in Core operating profit and the share
buyback, as well as lower net finance costs in the full year,
partly offset by higher non-controlling interests.
Currency impact on results
The
results for the year 2025 are based on average exchange rates,
principally $1.31/£1, €1.17/£1 and Yen198/£1.
The results for Q4 2025 are based on average exchange rates,
principally $1.33/£1, €1.14/£1 and Yen206/£1.
The period-end exchange rates were $1.35/£1,
€1.15/£1 and Yen211/£1. Comparative exchange rates
are given on page 38.
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
Q4 2025
|
||||
|
|
|
£m/£p
|
AER
|
CER
|
|
£m/£p
|
AER
|
CER
|
|
Turnover
|
|
32,667
|
4%
|
7%
|
|
8,618
|
6%
|
8%
|
|
Earnings
per share
|
Total
|
141.1p
|
>100%
|
>100%
|
|
15.8p
|
56%
|
65%
|
|
Core
|
172.0p
|
8%
|
12%
|
|
25.5p
|
10%
|
14%
|
|
In the
full year and Q4 2025, the adverse currency impact primarily
reflected the strengthening of Sterling against US Dollar as well
as emerging market currencies, partly offset by strengthening of
the Euro. Exchange gains on the settlement of intercompany
transactions had a favourable full year impact of three percentage
points on Total EPS and one percentage point on Core EPS. In the
quarter there was a favourable impact of six percentage points on
Total EPS and three percentage points on Core EPS.
|
|
|
Cash generation
|
|
|
|
|
|
|
|
|
|
|
Cash flow
|
|||||||
|
|
2025
£m
|
|
2024
£m
|
|
Q4 2025
£m
|
|
Q4
2024
£m
|
|
Cash
generated from operations (£m)
|
8,943
|
|
7,861
|
|
2,689
|
|
2,586
|
|
Total
net cash inflow/(outflow) from operating activities
(£m)
|
7,741
|
|
6,554
|
|
2,278
|
|
2,329
|
|
Free
cash inflow/(outflow)* (£m)
|
4,029
|
|
2,863
|
|
960
|
|
924
|
|
Free
cash flow growth (%)
|
41%
|
|
(16%)
|
|
4%
|
|
(56%)
|
|
Free
cash flow conversion* (%)
|
70%
|
|
>100%
|
|
>100%
|
|
>100%
|
|
Total
net debt** (£m)
|
14,453
|
|
13,095
|
|
14,453
|
|
13,095
|
|
|
|
|
*
|
Free cash flow and free cash flow conversion are defined on page
53. Free cash flow is analysed on page 42.
|
|
**
|
Net debt is analysed on page 42.
|
2025
Cash
generated from operating activities was £8,943 million (2024:
£7,861 million). The increase reflected higher Core operating
profit, favourable timing and movements on returns and rebates,
including the impact of the removal of the AMP cap in H1 2024, and
the cash settlements from CureVac as well as lower inventory build.
The increase was partly offset by an adverse movement in
receivables driven by higher Arexvy and Shingrix collections in Q1 2024, as
well as higher Zantac
settlement payments of £1,195 million (2024: £672
million).
Total
contingent consideration cash payments in 2025 were
£1,347 million (2024: £1,254 million).
£1,330 million (2024: £1,235 million) of these
were recognised in cash flows from operating activities, including
cash payments made to Shionogi & Co. Ltd (Shionogi) of
£1,277 million (2024:
£1,190 million).
Free
cash inflow was £4,029 million for 2025 (2024: £2,863
million). The increase was driven by higher cash generated from
operations, lower tax payments, lower capital expenditure on
property, plant and equipment, and higher dividends from joint
ventures and associates, partly offset by higher capital
expenditure on intangible assets and lower proceeds from the sale
of property, plant and equipment.
Q4 2025
Cash
generated from operations for the quarter was £2,689 million
(Q4 2024: £2,586 million). The increase primarily
reflected higher Core operating profit and lower Zantac settlement payments of £507
million (Q4 2024: £672 million), partly offset by adverse
timing and movements on returns and rebates.
Total
contingent consideration cash payments in the quarter were
£347 million (Q4 2024: £319 million).
£341 million (Q4 2024: £311 million) of these
were recognised in cash flows from operating activities, including
cash payments made to Shionogi of £321 million (Q4
2024: £290 million).
Free
cash inflow was £960 million for the quarter (Q4 2024:
£924 million). The increase was primarily driven by
higher cash generated from operations, lower capital expenditure on
intangible assets and higher dividends from joint ventures and
associates, partly offset by higher taxation payments and lower
proceeds from sale of property, plant and equipment.
Total Net debt
At 31
December 2025, net debt was £14,453 million, compared with
£13,095 million at 31 December 2024, comprising gross debt of
£17,859 million and cash and liquid investments of £3,406
million. See net debt information on page 42.
Net
debt increased by £1,358 million primarily due to the net
acquisition costs of IDRx, Inc. (IDRx), BP Asset IX, Inc. (BP Asset
IX) to access efimosfermin, and Cellphenomics GmbH totalling
£1,692 million, dividends paid to shareholders of £2,564
million and shares purchased as part of the share buyback programme
of £1,377 million. This was partly offset by free cash inflow
of £4,029 million and exchange gain on net debt of £241
million.
At 31
December 2025, GSK had short-term borrowings (including overdrafts
and lease liabilities) repayable within 12 months of £3,012
million and £1,487 million repayable in the subsequent
year.
Contents
|
|
|
|
|
Page
|
|
Q4 2025
pipeline highlights
|
14
|
|
Responsible
business
|
16
|
|
Total
and Core results
|
18
|
|
Income
statement
|
26
|
|
Statement
of comprehensive income
|
27
|
|
Balance
sheet
|
28
|
|
Statement
of changes in equity
|
29
|
|
Cash
flow statement
|
30
|
|
Sales
tables
|
31
|
|
Segment
information
|
34
|
|
Legal
matters
|
36
|
|
Returns
to shareholders
|
37
|
|
Additional
information
|
38
|
|
R&D
commentary
|
44
|
|
Reporting
definitions
|
53
|
|
Guidance
and outlooks, assumptions and cautionary statements
|
55
|
|
Glossary
of terms
|
57
|
Contacts
GSK plc
(LSE/NYSE:GSK) is a global biopharma company with a purpose to
unite science, technology, and talent to get ahead of disease
together. Find out more at www.gsk.com.
|
|
|
|
|
|
GSK enquiries:
|
|
|
|
|
Media
|
Tim
Foley
|
+44 (0)
7780 494750
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington)
|
|
|
|
|
|
|
Investor
Relations
|
Constantin
Fest
|
+44 (0)
7831 826525
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
7881 269066
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 3126
|
(Philadelphia)
|
|
|
|
|
|
|
Registered in England & Wales:
No.
3888792
|
|||
|
|
|||
|
Registered Office:
79 New
Oxford Street
London,
WC1A
1DG
|
|||
Q4 2025 pipeline highlights (since
29 October 2025)
|
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
Regulatory approvals or other regulatory actions
|
Exdensur
|
SWIFT-1/2
(severe asthma with type 2 inflammation)
|
Regulatory
approval (US)
|
|
Exdensur
|
SWIFT-1/2,
ANCHOR-1/2 (severe asthma with type 2 inflammation and chronic
rhinosinusitis with nasal polyps)
|
Regulatory
approval (JP, UK)
|
|
|
Exdensur
|
SWIFT-1/2,
ANCHOR-1/2 (severe asthma with type 2 inflammation and chronic
rhinosinusitis with nasal polyps)
|
Positive
CHMP opinion (EU)
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Positive
CHMP opinion (EU)
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Regulatory
approval (CN)
|
|
|
Trelegy
|
CAPTAIN
(asthma)
|
Regulatory
approval (CN)
|
|
|
Arexvy
|
RSV,
adults aged 18 and above
|
Regulatory
approval (EU)
|
|
|
Blujepa
|
EAGLE-1
(urogenital gonorrhoea)
|
Regulatory
approval (US)
|
|
|
Shingrix
|
Shingles,
liquid formulation
|
Regulatory
approval (EU)
|
|
|
Regulatory submissions or acceptances
|
Arexvy
|
RSV,
adults aged 18+ immunocompromised
|
Regulatory
acceptance (US, EU, JP)
|
|
tebipenem
pivoxil
|
PIVOT-PO
(complicated urinary tract infection)
|
Regulatory
acceptance (US)
|
|
|
Phase III data readouts or other significant events
|
Arexvy
|
RSV,
adults aged 60+ years
|
Positive
phase III data readout (CN)
|
|
bepirovirsen
|
B-Well
1 and B-Well 2 (chronic hepatitis B)
|
Positive
phase III data readout
|
|
|
Jemperli
|
AZUR-1
(dMMR/MSI-H rectal cancer)
|
Commissioner's
National Priority Voucher (US)
|
|
|
risvutatug
rezetecan
|
Small
cell lung cancer
|
Orphan
Drug Designation (EU, US)
|
|
|
|
|
|
|
|
Anticipated pipeline milestones
|
||||
|
Timing
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
H1 2026
|
depemokimab
|
SWIFT-1/2
(severe asthma with type 2 inflammation)
|
Regulatory
decision
(EU,
CN)
|
|
depemokimab
|
ANCHOR-1/2
(chronic rhinosinusitis with nasal polyps)
|
Regulatory
decision
(EU,
CN)
|
|
|
depemokimab
|
NIMBLE
(severe asthma)
|
Phase
IIIb data readout*
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
decision
(US)
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
submission (JP, CN)
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Regulatory
decision (EU)
|
|
|
Blenrep
|
DREAMM-7
(2L+ multiple myeloma)
|
Regulatory
decision (CN)
|
|
|
Arexvy
|
RSV,
adults aged 60+ years
|
Regulatory
submission (CN)
|
|
|
Arexvy
|
RSV,
adults aged 18-49 years at increased risk
|
Regulatory
decision
(US,
JP)
|
|
|
bepirovirsen
|
B-WELL
1/2 (chronic hepatitis B)
|
Regulatory
submission
(US,
EU, CN, JP)
|
|
|
Bexsero
|
Meningococcal
B (infants)
|
Regulatory
submission (US)
|
|
|
tebipenem
pivoxil
|
PIVOT-PO
(complicated urinary tract infection)
|
Regulatory
decision (US)
|
*Non-registrational study
|
H2 2026
|
camlipixant
|
CALM-1/2
(refractory chronic cough)
|
Phase
III data readout
|
|
camlipixant
|
CALM-1/2
(refractory chronic cough)
|
Regulatory
submission (US, EU, JP)
|
|
|
depemokimab
|
OCEAN
(eosinophilic granulomatosis with polyangiitis)
|
Phase
III data readout
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
decision (EU)
|
|
|
Ventolin
|
Low
carbon MDI (asthma)
|
Regulatory
submission (EU)
|
|
|
Blenrep
|
DREAMM-8
(2L + multiple myeloma)
|
Regulatory
submission (CN)
|
|
|
Jemperli
|
AZUR-1
(rectal cancer)
|
Phase
II (pivotal) data readout
|
|
|
cabotegravir
|
Q4M
PrEP (HIV prevention)
|
Phase
II (pivotal) data readout
|
|
|
cabotegravir
|
Q4M
PrEP (HIV prevention)
|
Regulatory
submission (US)
|
|
|
Arexvy
|
RSV,
adults aged 18+ immunocompromised
|
Regulatory
decision (US, EU, JP)
|
|
|
bepirovirsen
|
B-WELL
1/2 (hepatitis B virus)
|
Regulatory
decision (US, JP)
|
|
|
Bexsero
|
Meningococcal
B (infants)
|
Regulatory
decision (US)
|
|
|
2027
|
camlipixant
|
CALM-1/2
(refractory chronic cough)
|
Regulatory
decision (US, EU, JP)
|
|
depemokimab
|
OCEAN
(Eosinophilic granulomatosis with polyangiitis)
|
Regulatory
submission (US, EU, CN, JP)
|
|
|
depemokimab
|
OCEAN
(Eosinophilic granulomatosis with polyangiitis)
|
Regulatory
decision (US)
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
decision (JP, CN)
|
|
|
Ventolin
|
Low
carbon MDI (asthma)
|
Regulatory
decision (EU)
|
|
|
Blenrep
|
DREAMM
8 (2L+ multiple myeloma)
|
Regulatory
decision (CN)
|
|
|
Jemperli
|
AZUR-1
(rectal cancer)
|
Regulatory
submission (US, EU, CN, JP)
|
|
|
Jemperli
|
AZUR-1
(rectal cancer)
|
Regulatory
decision (US, EU, JP)
|
|
|
cabotegravir
+ rilpivirine
|
CUATRO,
Q4M treatment (HIV)
|
Phase
III data readout
|
|
|
cabotegravir
|
Q4M
PrEP (HIV)
|
Regulatory
decision (US)
|
|
|
Arexvy
|
RSV,
adults aged 60+
|
Regulatory
decision (CN)
|
|
|
bepirovirsen
|
B-WELL
1/2 (chronic hepatitis B)
|
Regulatory
decision (EU, CN)
|
|
|
gepotidacin
|
EAGLE-2/3
(uncomplicated urinary tract infection)
|
Regulatory
submission (EU)
|
|
|
gepotidacin
|
EAGLE-1
(urogenital gonorrhoea)
|
Regulatory
submission (EU)
|
Refer to pages 44 to 52 for further details on several key
medicines and vaccines in development by therapy
area.
Trust: progress on our six priority
areas for responsible business
Building Trust by operating responsibly is integral to GSK’s
strategy and culture. This will support growth and returns to
shareholders, reduce risk, and help GSK’s people thrive while
delivering sustainable health impact at scale. The Company has
identified six Responsible Business focus areas that address what
is most material to GSK’s business and the issues that matter
the most to its stakeholders. Highlights below include activity
since Q3 2025 results. For more details on annual updates,
please see GSK's Responsible
Business Performance Report 2024(1).
Access
Commitment:
to make GSK’s vaccines and medicines available at value-based
prices that are sustainable for the business and implement access
strategies that increase the use of GSK’s vaccines and
medicines to treat and protect underserved people.
Progress
since Q3 2025:
|
|
|
|
●
|
In
November GSK marked 25 years of partnership with the World Health
Organization on its Global Programme to Eliminate Lymphatic
Filariasis (LF). To date, GSK has donated more than 12 billion
albendazole tablets to the programme. By donating this essential
treatment against LF, GSK continues to help reduce the burden of LF
in lower income countries, meaning that not only are more people
protected from this disease, but that more people can keep working
and contributing to their local economy. To date, 21 countries have
eliminated the disease which is testament to the partnership of the
WHO, with companies like GSK and most importantly country leaders,
communities and patients in endemic. More information can be found
here(2).
|
|
●
|
Performance
metrics related to access are updated annually with related details
in GSK's Responsible Business Performance
Report 2024(1) on page
11.
|
Global health and health security
Commitment:
develop novel products and technologies to treat and prevent
priority diseases, including pandemic threats.
Progress
since Q3 2025:
|
|
|
|
●
|
GSK and
ViiV have renewed their commitment to the Global Fund, pledging
£6 million to strengthen community-led responses to HIV,
tuberculosis and malaria in lower income countries. The commitment
will be matched by the Gates Foundation, bringing this total
investment in the Global Fund to £12 million. This commitment
reinforces the vital role of grassroots leadership in shaping
sustainable health solutions. More information can be found
here(3).
|
|
●
|
In
November, GSK and the Fleming Initiative announced six major new
research programmes building on GSK’s long-standing
commitment to addressing drug-resistant infections. These
programmes will harness some of the best scientific expertise and
the latest technologies, including advanced AI, to find new ways to
slow the progress of antimicrobial resistance. All of the new
programmes will begin by early 2026 and are fully funded for three
years. More information can be found here(4).
|
|
●
|
In
December, GSK was announced as the industry lead for END2AMR
(European Novel Drug Research to Address Microbial Infections and
Drug Resistance) – a new public-private research initiative
designed to tackle some of the most difficult-to-treat bacterial
infections. The project brings together leading academic groups,
research institutes, SMEs, and industry partners to develop a new
generation of antibacterial modalities and delivery technologies.
More information can be found here(5).
|
|
●
|
Performance
metrics related to global health and health security are updated
annually with related details in GSK's
Responsible Business Performance Report 2024(1) on
page 16.
|
Environment
Commitment:
committed to a net zero, nature-positive, healthier planet with
ambitious goals set for 2030 and 2045.
Progress
since Q3 2025:
|
|
|
|
●
|
GSK
retained its position on the CDP 2025 A List for Climate Change and
Water and scored a B for its Forest submission. Securing a place on
the A List means GSK is among the top 4% of companies scored by CDP
– the world's only independent system for environmental
disclosure.
|
|
●
|
GSK
worked with partners across the pharmaceutical industry and wider
healthcare systems to shape the development of a pharma-specific
framework to measure and report the environmental impact of
medicines, in response to increasing requirements from payers. The
new global standard has been published by BSI as PAS2090. More
information can be found here(6).
|
|
●
|
Performance
metrics related to environment are updated annually with related
details in GSK's Responsible Business Performance
Report 2024(1) on page
19.
|
Inclusion
Commitment:
meet patients’ needs with research that includes those
impacted by the disease under study, attract and retain the best
talent regardless of background, and support all GSK people to
thrive.
|
|
|
|
●
|
Performance
metrics related to inclusion are updated annually with related
details in GSK's Responsible Business Performance
Report 2024(1) on page
27.
|
Ethical standards
Commitment:
promote ethical behaviour across GSK’s business by supporting
its employees to do the right thing and working with suppliers that
share GSK’s standards and operate responsibly.
|
|
|
|
●
|
Performance
metrics related to ethical standards are updated annually with
related details in GSK's Responsible Business Performance
Report 2024(1) on page
29.
|
Product governance
Commitment:
maintain robust quality and safety processes and responsibly use
data and new technologies.
|
|
|
|
●
|
Performance
metrics related to product governance are updated annually with
related details in GSK's Responsible Business Performance Report
2024(1)
on page 34.
|
Responsible Business rating performance
Detailed
below is how GSK performs in key Responsible Business
ratings(7).
|
External
benchmark
|
Current
score/ranking
|
Previous
score/ranking
|
Comments
|
|
Access
to Medicines Index
|
3.72
|
4.06
|
Second
in the Index, updated bi-annually, current results from November
2024. Score ranging from 0 to 5
|
|
Antimicrobial
resistance benchmark
|
84%
|
86%
|
Led the
benchmark since its inception in 2018; Current ranking updated
November 2021
|
|
CDP
Climate Change
|
A
|
A
|
Updated
annually, current scores updated December 2025 (for supplier
engagement, July 2025)
|
|
CDP
Water Security
|
A
|
A
|
|
|
CDP
Forests (palm oil)
|
B
|
B
|
|
|
CDP
Forests (timber)
|
B
|
B
|
|
|
CDP
supplier engagement rating
|
Leader
|
Leader
|
|
|
Sustainalytics
|
13.7
|
14.8
|
1st
percentile in pharma subindustry group; lower score represents
lower risk. Current score as at October 2025
|
|
MSCI
|
AA
|
AA
|
Last
rating action date: September 2023
|
|
ISS
Corporate Rating
|
B+
|
B+
|
Current
score updated October 2024
|
|
FTSE4Good
|
Member
|
Member
|
Member
since 2004, latest review in June 2024
|
|
ShareAction’s
Workforce Disclosure Initiative
|
79%
|
77%
|
Current
score updated January 2024
|
Footnotes:
|
|
|
(1)
https://www.gsk.com/media/11863/responsible-business-performance-report-2024.pdf
|
|
(2)
https://www.linkedin.com/posts/thomas-breuer-md-msc_25-years-of-partnership-to-fight-lfmp4-activity-7400201399789068288-pqKH/
|
|
(3)
https://www.gsk.com/en-gb/media/press-releases/global-fund-welcomes-renewed-commitment-from-gsk-and-viiv-healthcare-to-expand-community-led-health-solutions-with-6-million-joint-pledge/
|
|
(4)
https://www.gsk.com/en-gb/media/press-releases/gsk-and-fleming-initiative-scientists-unite-to-target-amr-with-advanced-ai/
|
|
(5)
https://www.lygature.org/news/end2amr-launches-accelerate-innovation-against-drug-resistant-bacterial-infections
|
|
(6)
https://knowledge.bsigroup.com/products/pharmaceutical-products-product-category-rules-for-life-cycle-assessments-specification
|
|
(7) GSK’s Responsible
Business ratings are regularly reviewed to ensure the external
benchmarks listed remain high quality, appropriate and relevant to
investors. The outcome of these reviews may lead to changes on
which ratings are included in the table above – last updated
July 2025.
|
Total and Core
results
Total
reported results represent the Group’s overall
performance.
GSK
uses a number of non-IFRS measures to report the performance of its
business. Core results and other non-IFRS measures may be
considered in addition to, but not as a substitute for, or superior
to, information presented in accordance with IFRS. Core results are
defined below and other non-IFRS measures are defined on pages 53
and 54.
GSK
believes that Core results, when considered together with Total
results, provide investors, analysts and other stakeholders with
helpful complementary information to understand better the
financial performance and position of the Group from period to
period, and allow the Group’s performance to be more easily
compared against the majority of its peer companies. These measures
are also used by management for planning and reporting purposes.
They may not be directly comparable with similarly described
measures used by other companies.
GSK
encourages investors and analysts not to rely on any single
financial measure but to review GSK’s quarterly results
announcements, including the financial statements and notes, in
their entirety.
GSK is
committed to continuously improving its financial reporting, in
line with evolving regulatory requirements and best practice. In
line with this practice, GSK expects to continue to review and
refine its reporting framework.
Core
results exclude the following items in relation to our operations
from Total results, together with the tax effects of all of these
items:
|
|
|
|
●
|
amortisation
of intangible assets (excluding computer software and capitalised
development costs)
|
|
●
|
impairment
of intangible assets (excluding computer software) and
goodwill
|
|
●
|
major
restructuring costs, which include impairments of tangible assets
and computer software, (under specific Board approved programmes
that are structural, of a significant scale and where the costs of
individual or related projects exceed £25 million), including
integration costs following material acquisitions
|
|
●
|
transaction-related
accounting or other adjustments related to significant
acquisitions
|
|
●
|
proceeds
and costs of disposal of associates, products and businesses;
significant settlement income; Significant legal charges (net of
insurance recoveries) and expenses on the settlement of litigation
and government investigations; other operating income other than
royalty income, and other items including amounts reclassified from
the foreign currency translation reserve to the income statement
upon the liquidation of a subsidiary where the amount exceeds
£25 million
|
Costs
for all other ordinary course smaller scale restructuring and legal
charges and expenses from operations are retained within both Total
and Core results.
As Core
results include the benefits of Major restructuring programmes but
exclude significant costs (such as Significant legal charges and
expenses, major restructuring costs and transaction items) they
should not be regarded as a complete picture of the Group’s
financial performance, which is presented in Total results. The
exclusion of other Adjusting items may result in Core earnings
being materially higher or lower than Total earnings. In
particular, when significant impairments, restructuring charges and
legal costs are excluded, Core earnings will be higher than Total
earnings.
GSK has
undertaken a number of Major restructuring programmes in response
to significant changes in the Group’s trading environment or
overall strategy or following material acquisitions. Within the
Pharmaceuticals sector, the highly regulated manufacturing
operations and supply chains and long lifecycle of the business
mean that restructuring programmes, particularly those that involve
the rationalisation or closure of manufacturing or R&D sites
are likely to take several years to complete. Costs, both cash and
non-cash, of these programmes are provided for as individual
elements are approved and meet the accounting recognition criteria.
As a result, charges may be incurred over a number of years
following the initiation of a Major restructuring
programme.
Significant
legal charges and expenses are those arising from the settlement of
litigation or government investigations that are not in the normal
course and materially larger than more regularly occurring
individual matters. They also include certain major legacy
matters.
Reconciliations
between Total and Core results, providing further information on
the key Adjusting items, are set out on pages 20-23.
GSK
provides earnings guidance to the investor community on the basis
of Core results. This is in line with peer companies and
expectations of the investor community, supporting easier
comparison of the Group’s performance with its peers. GSK is
not able to give guidance for Total results as it cannot reliably
forecast certain material elements of the Total results,
particularly the future fair value movements on contingent
consideration and put options that can and have given rise to
significant adjustments driven by external factors such as currency
and other movements in capital markets.
ViiV Healthcare
ViiV
Healthcare is a subsidiary of the Group and 100% of its operating
results (turnover, operating profit, profit after tax) are included
within the Group income statement.
Earnings
for the year are allocated to the three shareholders of ViiV
Healthcare on the basis of their respective equity shareholdings
(GSK 78.3%, Pfizer 11.7% and Shionogi 10%) and their entitlement to
preferential dividends, which are determined by the performance of
certain products that each shareholder contributed. As the relative
performance of these products changes over time, the proportion of
the overall earnings allocated to each shareholder also changes. In
particular, the increasing proportion of sales of dolutegravir and
cabotegravir-containing products has a favourable impact on the
proportion of the preferential dividends that is allocated to GSK.
Adjusting items are allocated to shareholders based on their equity
interests. GSK was entitled to approximately 83% of the Total
earnings and 83% of the Core earnings of ViiV Healthcare for
2025.
As
consideration for the acquisition of Shionogi’s interest in
the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi
received the 10% equity stake in ViiV Healthcare and ViiV
Healthcare also agreed to pay additional future cash consideration
to Shionogi, contingent on the future sales performance of the
products being developed by that joint venture, dolutegravir and
cabotegravir. Under IFRS 3 ‘Business combinations’, GSK
was required to provide for the estimated fair value of this
contingent consideration at the time of acquisition and is required
to update the liability to the latest estimate of fair value at
each subsequent period end. The liability for the contingent
consideration recognised in the balance sheet at the date of
acquisition was £659 million. Subsequent remeasurements are
reflected within other operating income/(expense) and within
Adjusting items in the income statement in each
period.
Cash
payments to settle the contingent consideration are made to
Shionogi by ViiV Healthcare each quarter, based on the actual sales
performance and other income of the relevant products in the
previous quarter. These payments reduce the balance sheet liability
and hence are not recorded in the income statement. The cash
payments made to Shionogi by ViiV Healthcare in the year ended 31
December 2025 were £1,277 million.
As the
liability is required to be recorded at the fair value of estimated
future payments, there is a significant timing difference between
the charges that are recorded in the Total income statement to
reflect movements in the fair value of the liability and the actual
cash payments made to settle the liability.
Further
explanation of the acquisition-related arrangements with ViiV
Healthcare are set out on pages 89 and 90 of the Annual Report
2024.
On 19
January 2026, GSK reached agreement with Pfizer and Shionogi for
the 11.7% economic interest in ViiV Healthcare currently held by
Pfizer to be replaced with an investment by Shionogi. Details of
this agreement are set out in the post balance sheet event on page
43.
The
reconciliations between Total results and Core results for 2025 and
2024 are set out below.
Year ended 31 December 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
|
Intangible
asset
amort-
isation
£m
|
|
Intangible
asset
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Significant
legal,
Divest-
ments
and
other
items
£m
|
|
Core
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
32,667
|
|
|
|
|
|
|
|
|
|
|
|
32,667
|
|
Cost of
sales
|
(9,017)
|
|
722
|
|
22
|
|
48
|
|
|
|
19
|
|
(8,206)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
23,650
|
|
722
|
|
22
|
|
48
|
|
|
|
19
|
|
24,461
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(9,088)
|
|
|
|
|
|
44
|
|
23
|
|
32
|
|
(8,989)
|
|
Research
and development
|
(7,525)
|
|
86
|
|
858
|
|
17
|
|
(4)
|
|
|
|
(6,568)
|
|
Royalty
income
|
879
|
|
|
|
|
|
|
|
|
|
|
|
879
|
|
Other
operating income/(expense)
|
16
|
|
|
|
|
|
|
|
488
|
|
(504)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
7,932
|
|
808
|
|
880
|
|
109
|
|
507
|
|
(453)
|
|
9,783
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance expense
|
(532)
|
|
|
|
|
|
|
|
|
|
24
|
|
(508)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
1
|
|
|
|
|
|
|
|
|
|
(11)
|
|
(10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
7,401
|
|
808
|
|
880
|
|
109
|
|
507
|
|
(440)
|
|
9,265
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(1,112)
|
|
(178)
|
|
(220)
|
|
(32)
|
|
(147)
|
|
105
|
|
(1,584)
|
|
Tax rate %
|
15.0%
|
|
|
|
|
|
|
|
|
|
|
|
17.1%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
6,289
|
|
630
|
|
660
|
|
77
|
|
360
|
|
(335)
|
|
7,681
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
573
|
|
|
|
|
|
|
|
139
|
|
|
|
712
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit/(loss)
attributable to shareholders
|
5,716
|
|
630
|
|
660
|
|
77
|
|
221
|
|
(335)
|
|
6,969
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,289
|
|
630
|
|
660
|
|
77
|
|
360
|
|
(335)
|
|
7,681
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
141.1p
|
|
15.6p
|
|
16.3p
|
|
1.9p
|
|
5.4p
|
|
(8.3p)
|
|
172.0p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
number of shares (millions)
|
4,051
|
|
|
|
|
|
|
|
|
|
|
|
4,051
|
Year ended 31 December 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
|
Intangible
asset
amort-
isation
£m
|
|
Intangible
asset
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Significant
legal,
Divest-
ments
and
other
items
£m
|
|
Core
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
31,376
|
|
|
|
|
|
|
|
|
|
|
|
31,376
|
|
Cost of
sales
|
(9,048)
|
|
947
|
|
|
|
163
|
|
40
|
|
28
|
|
(7,870)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
22,328
|
|
947
|
|
|
|
163
|
|
40
|
|
28
|
|
23,506
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(11,015)
|
|
|
|
|
|
160
|
|
2
|
|
1,879
|
|
(8,974)
|
|
Research
and development
|
(6,401)
|
|
55
|
|
314
|
|
9
|
|
|
|
|
|
(6,023)
|
|
Royalty
income
|
639
|
|
|
|
|
|
|
|
|
|
|
|
639
|
|
Other
operating income/(expense)
|
(1,530)
|
|
|
|
|
|
21
|
|
1,839
|
|
(330)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
4,021
|
|
1,002
|
|
314
|
|
353
|
|
1,881
|
|
1,577
|
|
9,148
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance expense
|
(547)
|
|
|
|
|
|
1
|
|
|
|
14
|
|
(532)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
(3)
|
|
Profit/(loss) on
disposal of interest in associates
|
6
|
|
|
|
|
|
|
|
|
|
(6)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
3,477
|
|
1,002
|
|
314
|
|
354
|
|
1,881
|
|
1,585
|
|
8,613
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(526)
|
|
(208)
|
|
(63)
|
|
(80)
|
|
(311)
|
|
(274)
|
|
(1,462)
|
|
Tax rate %
|
15.1%
|
|
|
|
|
|
|
|
|
|
|
|
17.0%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
2,951
|
|
794
|
|
251
|
|
274
|
|
1,570
|
|
1,311
|
|
7,151
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
376
|
|
|
|
|
|
|
|
278
|
|
|
|
654
|
|
Profit/(loss) attributable to shareholders
|
2,575
|
|
794
|
|
251
|
|
274
|
|
1,292
|
|
1,311
|
|
6,497
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,951
|
|
794
|
|
251
|
|
274
|
|
1,570
|
|
1,311
|
|
7,151
|
|
Earnings per share
|
63.2p
|
|
19.5p
|
|
6.1p
|
|
6.7p
|
|
31.7p
|
|
32.1p
|
|
159.3p
|
|
Weighted average
number of shares (millions)
|
4,077
|
|
|
|
|
|
|
|
|
|
|
|
4,077
|
Adjusting items full year
2025
Major restructuring and integration
|
|
|
Charges
of £109 million (2024: £353 million) were incurred
relating to ongoing projects categorised as Major restructuring
programmes, analysed as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
2024
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Separation
restructuring programme
|
48
|
|
14
|
|
62
|
|
200
|
|
36
|
|
236
|
|
Significant
acquisitions
|
26
|
|
–
|
|
26
|
|
59
|
|
1
|
|
60
|
|
Legacy
programmes
|
13
|
|
8
|
|
21
|
|
48
|
|
9
|
|
57
|
|
|
87
|
|
22
|
|
109
|
|
307
|
|
46
|
|
353
|
The
Separation restructuring programme incurred cash charges of
£48 million primarily from the restructuring of some
commercial and administrative functions. The non-cash charges of
£14 million primarily reflected the write-down of assets in
manufacturing locations.
The
programme focussed on the separation of GSK into two separate
companies and is now largely complete. The programme has delivered
its target of £1.1 billion of annual savings, with total costs
still expected at £2.4 billion, with cash charges of £1.7
billion and non-cash charges of £0.7 billion.
Costs
of significant acquisitions relate to integration costs of
Affinivax Inc. (Affinivax) which was acquired in Q3 2022, BELLUS
Health Inc. (Bellus) acquired in Q2 2023, Aiolos Bio, Inc. (Aiolos)
acquired in Q1 2024, IDRx acquired in Q1 2025 and BP Asset IX
acquired to access efimosfermin in Q3 2025.
Cash
charges of £13 million under Legacy programmes primarily arose
from the divestment of the cephalosporins business.
Transaction-related adjustments
Transaction-related
adjustments resulted in a net charge of £507 million (2024:
£1,881 million), the majority of which related to
charges/(credits) for the remeasurement of contingent consideration
liabilities, the liabilities for the Pfizer put option, and Pfizer
and Shionogi preferential dividends in ViiV
Healthcare.
|
|
|
|
|
|
Charge/(credit)
|
2025
£m
|
|
2024
£m
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint venture
(including Shionogi preferential dividends)
|
649
|
|
1,533
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
(93)
|
|
67
|
|
Contingent
consideration on former Novartis Vaccines business
|
171
|
|
206
|
|
Contingent
consideration on acquisition of Affinivax
|
(254)
|
|
(22)
|
|
Other
contingent consideration
|
15
|
|
34
|
|
Other
adjustments
|
19
|
|
63
|
|
Total
transaction-related charges
|
507
|
|
1,881
|
The
£649 million charge relating to the contingent consideration
for the former Shionogi-ViiV Healthcare joint venture represented
an increase in the valuation of the contingent consideration due to
Shionogi, driven by the unwind of the discount for £404
million and net other remeasurements of £245 million. The
£93 million credit relating to the ViiV Healthcare put option
and Pfizer preferential dividends represented a decrease in the
valuation of the put option primarily as a result of updated
exchange rates and sales forecasts. The ViiV Healthcare contingent
consideration liability is fair valued under IFRS. An explanation
of the accounting for the non-controlling interests in ViiV
Healthcare is set out on page 19.
The
£171 million charge relating to the contingent consideration
on the former Novartis Vaccines business primarily related to
changes to future sales forecasts, updated exchange rates and the
unwind of the discount.
The
£254 million credit relating to the contingent consideration
on the acquisition of Affinivax primarily related to updated
milestone forecasts, partly offset by the unwind of the
discount.
Significant legal charges, Divestments, and other
items
Legal
charges provide for all significant legal matters and are not
broken out separately by litigation or investigation.
Divestments
and other items included the £367 million ($500 million) of
settlements from CureVac in connection with the mRNA patent
settlement, as well as other net income, including income from
divestments and fair value movements on, and distributions from,
equity investments.
The
reconciliations between Total results and Core results for Q4 2025
and Q4 2024 are set out below.
Three months ended 31 December 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
|
Intangible
asset
amort-
isation
£m
|
|
Intangible
asset
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Significant
legal,
Divest-
ments
and
other
items
£m
|
|
Core
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
8,618
|
|
|
|
|
|
|
|
|
|
|
|
8,618
|
|
Cost of
sales
|
(2,657)
|
|
176
|
|
22
|
|
18
|
|
|
|
6
|
|
(2,435)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
5,961
|
|
176
|
|
22
|
|
18
|
|
|
|
6
|
|
6,183
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,639)
|
|
|
|
|
|
(10)
|
|
(25)
|
|
(3)
|
|
(2,677)
|
|
Research
and development
|
(2,350)
|
|
21
|
|
206
|
|
10
|
|
(4)
|
|
|
|
(2,117)
|
|
Royalty
income
|
245
|
|
|
|
|
|
|
|
|
|
|
|
245
|
|
Other
operating income/(expense)
|
(117)
|
|
|
|
|
|
|
|
295
|
|
(178)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
1,100
|
|
197
|
|
228
|
|
18
|
|
266
|
|
(175)
|
|
1,634
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance expense
|
(149)
|
|
|
|
|
|
|
|
|
|
(1)
|
|
(150)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(1)
|
|
|
|
|
|
|
|
|
|
(2)
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
950
|
|
197
|
|
228
|
|
18
|
|
266
|
|
(178)
|
|
1,481
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(223)
|
|
(44)
|
|
(57)
|
|
(10)
|
|
(13)
|
|
91
|
|
(256)
|
|
Tax rate %
|
23.5%
|
|
|
|
|
|
|
|
|
|
|
|
17.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
727
|
|
153
|
|
171
|
|
8
|
|
253
|
|
(87)
|
|
1,225
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
91
|
|
|
|
|
|
|
|
108
|
|
|
|
199
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit/(loss) attributable to shareholders
|
636
|
|
153
|
|
171
|
|
8
|
|
145
|
|
(87)
|
|
1,026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
727
|
|
153
|
|
171
|
|
8
|
|
253
|
|
(87)
|
|
1,225
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
15.8p
|
|
3.8p
|
|
4.3p
|
|
0.2p
|
|
3.6p
|
|
(2.2p)
|
|
25.5p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
number of shares (millions)
|
4,019
|
|
|
|
|
|
|
|
|
|
|
|
4,019
|
Three months ended 31 December 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
|
Intangible
asset
amort-
isation
£m
|
|
Intangible
asset
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Significant
legal,
Divest-
ments
and
other
items
£m
|
|
Core
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
8,117
|
|
|
|
|
|
|
|
|
|
|
|
8,117
|
|
Cost of
sales
|
(2,559)
|
|
183
|
|
|
|
22
|
|
|
|
15
|
|
(2,339)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
5,558
|
|
183
|
|
|
|
22
|
|
|
|
15
|
|
5,778
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,663)
|
|
|
|
|
|
35
|
|
1
|
|
(75)
|
|
(2,702)
|
|
Research
and development
|
(2,031)
|
|
15
|
|
196
|
|
(1)
|
|
|
|
|
|
(1,821)
|
|
Royalty
income
|
176
|
|
|
|
|
|
|
|
|
|
|
|
176
|
|
Other
operating income/(expense)
|
(344)
|
|
|
|
|
|
16
|
|
417
|
|
(89)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
696
|
|
198
|
|
196
|
|
72
|
|
418
|
|
(149)
|
|
1,431
|
|
Net
finance expense
|
(139)
|
|
|
|
|
|
|
|
|
|
1
|
|
(138)
|
|
Profit/(loss) on
disposal of interest in associates and joint ventures
|
6
|
|
|
|
|
|
|
|
|
|
(6)
|
|
–
|
|
Profit before taxation
|
563
|
|
198
|
|
196
|
|
72
|
|
418
|
|
(154)
|
|
1,293
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(62)
|
|
(36)
|
|
(35)
|
|
(11)
|
|
(11)
|
|
(19)
|
|
(174)
|
|
Tax rate %
|
11.0%
|
|
|
|
|
|
|
|
|
|
|
|
13.5%
|
|
Profit after taxation
|
501
|
|
162
|
|
161
|
|
61
|
|
407
|
|
(173)
|
|
1,119
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
87
|
|
|
|
|
|
|
|
86
|
|
|
|
173
|
|
Profit/(loss)
attributable to shareholders
|
414
|
|
162
|
|
161
|
|
61
|
|
321
|
|
(173)
|
|
946
|
|
|
501
|
|
162
|
|
161
|
|
61
|
|
407
|
|
(173)
|
|
1,119
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
10.1p
|
|
4.0p
|
|
3.9p
|
|
1.5p
|
|
7.9p
|
|
(4.2p)
|
|
23.2p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
number of shares (millions)
|
4,081
|
|
|
|
|
|
|
|
|
|
|
|
4,081
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusting items Q4
2025
Major restructuring and integration
Charges
of £18 million (Q4 2024: £72 million) were incurred
relating to ongoing projects categorised as Major restructuring
programmes, analysed as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q4 2025
|
|
Q4
2024
|
||||||||
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Separation
restructuring programme
|
(1)
|
|
(3)
|
|
(4)
|
|
31
|
|
22
|
|
53
|
|
Significant
acquisitions
|
14
|
|
–
|
|
14
|
|
9
|
|
–
|
|
9
|
|
Legacy
programmes
|
2
|
|
6
|
|
8
|
|
1
|
|
9
|
|
10
|
|
|
15
|
|
3
|
|
18
|
|
41
|
|
31
|
|
72
|
The
credits on the Separation restructuring programme of £1
million in cash and £3 million in non-cash are primarily from
releases of restructuring provisions for some commercial functions.
The programme focussed on the separation of GSK into two separate
companies and is now largely complete.
Costs
of significant acquisitions relate to integration costs of
Affinivax which was acquired in Q3 2022, Bellus acquired in Q2
2023, Aiolos acquired in Q1 2024, IDRx acquired in Q1 2025 and BP
Asset IX acquired to access efimosfermin in Q3 2025.
Transaction-related adjustments
Transaction-related
adjustments resulted in a net charge of £266 million (Q4 2024:
£418 million), the majority of which related to
charges/(credits) for the remeasurement of contingent consideration
liabilities on acquisition of Affinivax, Novartis vaccines business
and Pfizer and Shionogi preferential dividends in ViiV
Healthcare.
|
|
|
|
|
|
Charge/(credit)
|
Q4 2025
£m
|
|
Q4
2024
£m
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint venture
(including Shionogi preferential dividends)
|
488
|
|
427
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
3
|
|
13
|
|
Contingent
consideration on former Novartis Vaccines business
|
37
|
|
–
|
|
Contingent
consideration on acquisition of Affinivax
|
(238)
|
|
(53)
|
|
Other
contingent consideration
|
5
|
|
29
|
|
Other
adjustments
|
(29)
|
|
2
|
|
Total
transaction-related charges/(credits)
|
266
|
|
418
|
The
£488 million charge relating to the contingent consideration
for the former Shionogi-ViiV Healthcare joint venture represented
an increase in the valuation of the contingent consideration due to
Shionogi driven by updated sales forecasts and net other
remeasurements of £392 million and the unwind of the discount
for £96 million. An explanation of the accounting for the
non-controlling interests in ViiV Healthcare is set out on page
19.
There
was a £37 million charge in the quarter relating to the
contingent consideration on the former Novartis Vaccines business
primarily related to updated exchange rates and the unwind of the
discount.
The
£238 million credit relating to the contingent consideration
on the acquisition of Affinivax primarily related to updated
milestone forecasts, partly offset by the unwind of the
discount.
Significant legal charges, Divestments, and other
items
Legal
charges provide for all significant legal matters and are not
broken out separately by litigation or investigation.
Divestments
and other items included the £99 million ($130 million)
settlement from CureVac in connection with the mRNA patent
settlement, as well as other net income, including income from
divestments and fair value movements on, and distributions from,
equity investments.
|
|
|
Financial
information
|
|
|
|
|
Income statement
|
|
|
|
|
|
|
|
|
|
|
2025
£m
|
|
2024
£m
|
|
Q4 2025
£m
|
|
Q4
2024
£m
|
|
|
|
|
|
|
|
|
|
|
TURNOVER
|
32,667
|
|
31,376
|
|
8,618
|
|
8,117
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(9,017)
|
|
(9,048)
|
|
(2,657)
|
|
(2,559)
|
|
Gross
profit
|
23,650
|
|
22,328
|
|
5,961
|
|
5,558
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(9,088)
|
|
(11,015)
|
|
(2,639)
|
|
(2,663)
|
|
Research
and development
|
(7,525)
|
|
(6,401)
|
|
(2,350)
|
|
(2,031)
|
|
Royalty
income
|
879
|
|
639
|
|
245
|
|
176
|
|
Other
operating income/(expense)
|
16
|
|
(1,530)
|
|
(117)
|
|
(344)
|
|
|
|
|
|
|
|
|
|
|
OPERATING PROFIT
|
7,932
|
|
4,021
|
|
1,100
|
|
696
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
169
|
|
122
|
|
39
|
|
34
|
|
Finance
expense
|
(701)
|
|
(669)
|
|
(188)
|
|
(173)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
1
|
|
(3)
|
|
(1)
|
|
–
|
|
Profit/(loss)
on disposal of interests in associates and joint
ventures
|
–
|
|
6
|
|
–
|
|
6
|
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE TAXATION
|
7,401
|
|
3,477
|
|
950
|
|
563
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(1,112)
|
|
(526)
|
|
(223)
|
|
(62)
|
|
Tax rate %
|
15.0%
|
|
15.1%
|
|
23.5%
|
|
11.0%
|
|
PROFIT AFTER TAXATION
|
6,289
|
|
2,951
|
|
727
|
|
501
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
573
|
|
376
|
|
91
|
|
87
|
|
Profit
attributable to shareholders
|
5,716
|
|
2,575
|
|
636
|
|
414
|
|
|
6,289
|
|
2,951
|
|
727
|
|
501
|
|
|
|
|
|
|
|
|
|
|
EARNINGS PER SHARE
|
141.1p
|
|
63.2p
|
|
15.8p
|
|
10.1p
|
|
|
|
|
|
|
|
|
|
|
Diluted
earnings per share
|
138.8p
|
|
62.2p
|
|
15.6p
|
|
10.0p
|
Statement of comprehensive income
|
|
|
|
|
|
|
|
|
|
|
2025
£m
|
|
2024
£m
|
|
Q4 2025
£m
|
|
Q4
2024
£m
|
|
Total
profit for the period
|
6,289
|
|
2,951
|
|
727
|
|
501
|
|
|
|
|
|
|
|
|
|
|
Items that may be reclassified subsequently to income
statement:
|
|
|
|
|
|
|
|
|
Exchange movements
on overseas net assets and net investment hedges
|
231
|
|
(392)
|
|
(61)
|
|
(345)
|
|
Reclassification of
exchange movements on liquidation or disposal of overseas
subsidiaries and associates
|
(12)
|
|
(87)
|
|
(3)
|
|
(31)
|
|
Fair
value movements on cash flow hedges
|
(41)
|
|
–
|
|
(8)
|
|
1
|
|
Cost of
hedging
|
4
|
|
(4)
|
|
(8)
|
|
1
|
|
Reclassification
of cash flow hedges to income statement
|
36
|
|
4
|
|
7
|
|
–
|
|
Deferred
tax on fair value movements on cash flow hedges
|
(2)
|
|
1
|
|
(1)
|
|
2
|
|
|
216
|
|
(478)
|
|
(74)
|
|
(372)
|
|
|
|
|
|
|
|
|
|
|
Items that will not be reclassified to income
statement:
|
|
|
|
|
|
|
|
|
Exchange movements
on overseas net assets of non-controlling interests
|
(18)
|
|
(4)
|
|
(4)
|
|
13
|
|
Fair
value movements on equity investments
|
215
|
|
(100)
|
|
134
|
|
8
|
|
Tax on
fair value movements on equity investments
|
(20)
|
|
17
|
|
(6)
|
|
11
|
|
Fair
value movements on cash flow hedges
|
–
|
|
8
|
|
–
|
|
6
|
|
Remeasurement
gains/(losses) on defined benefit plans
|
133
|
|
506
|
|
1
|
|
133
|
|
Tax
(charge)/credit on remeasurement of defined benefit
plans
|
(33)
|
|
(122)
|
|
(2)
|
|
(35)
|
|
|
277
|
|
305
|
|
123
|
|
136
|
|
|
|
|
|
|
|
|
|
|
Other
comprehensive income/(expense) for the period
|
493
|
|
(173)
|
|
49
|
|
(236)
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period
|
6,782
|
|
2,778
|
|
776
|
|
265
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period attributable to:
|
|
|
|
|
|
|
|
|
Shareholders
|
6,227
|
|
2,406
|
|
689
|
|
165
|
|
Non-controlling interests
|
555
|
|
372
|
|
87
|
|
100
|
|
|
6,782
|
|
2,778
|
|
776
|
|
265
|
Balance sheet
|
|
|
|
|
|
|
31 December 2025
£m
|
|
31
December 2024
£m
|
|
ASSETS
|
|
|
|
|
Non-current assets
|
|
|
|
|
Property,
plant and equipment
|
9,322
|
|
9,227
|
|
Right
of use assets
|
726
|
|
846
|
|
Goodwill
|
7,018
|
|
6,982
|
|
Other
intangible assets
|
16,748
|
|
15,515
|
|
Investments
in associates and joint ventures
|
89
|
|
96
|
|
Other
investments
|
1,037
|
|
1,100
|
|
Deferred
tax assets
|
6,520
|
|
6,757
|
|
Derivative
financial instruments
|
–
|
|
1
|
|
Other
non-current assets
|
2,148
|
|
1,942
|
|
|
|
|
|
|
Total non-current assets
|
43,608
|
|
42,466
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
Inventories
|
5,924
|
|
5,669
|
|
Current
tax recoverable
|
288
|
|
489
|
|
Trade
and other receivables
|
7,471
|
|
6,836
|
|
Derivative
financial instruments
|
121
|
|
109
|
|
Liquid
investments
|
9
|
|
21
|
|
Cash
and cash equivalents
|
3,397
|
|
3,870
|
|
Assets
held for sale
|
300
|
|
3
|
|
|
|
|
|
|
Total current assets
|
17,510
|
|
16,997
|
|
|
|
|
|
|
TOTAL ASSETS
|
61,118
|
|
59,463
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
Current liabilities
|
|
|
|
|
Short-term
borrowings
|
(3,012)
|
|
(2,349)
|
|
Contingent
consideration liabilities
|
(1,348)
|
|
(1,172)
|
|
Trade
and other payables
|
(15,381)
|
|
(15,335)
|
|
Derivative
financial instruments
|
(75)
|
|
(192)
|
|
Current
tax payable
|
(498)
|
|
(703)
|
|
Short-term
provisions
|
(938)
|
|
(1,946)
|
|
Liabilities
relating to assets held for sale
|
(139)
|
|
–
|
|
|
|
|
|
|
Total current liabilities
|
(21,391)
|
|
(21,697)
|
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
Long-term
borrowings
|
(14,708)
|
|
(14,637)
|
|
Deferred
tax liabilities
|
(291)
|
|
(382)
|
|
Pensions
and other post-employment benefits
|
(1,687)
|
|
(1,864)
|
|
Derivative
financial instruments
|
(67)
|
|
–
|
|
Other
provisions
|
(610)
|
|
(589)
|
|
Contingent
consideration liabilities
|
(5,385)
|
|
(6,108)
|
|
Other
non-current liabilities
|
(1,023)
|
|
(1,100)
|
|
|
|
|
|
|
Total non-current liabilities
|
(23,771)
|
|
(24,680)
|
|
|
|
|
|
|
TOTAL LIABILITIES
|
(45,162)
|
|
(46,377)
|
|
|
|
|
|
|
NET ASSETS
|
15,956
|
|
13,086
|
|
|
|
|
|
|
EQUITY
|
|
|
|
|
Share
capital
|
1,349
|
|
1,348
|
|
Share
premium account
|
3,498
|
|
3,473
|
|
Retained
earnings
|
10,209
|
|
7,796
|
|
Other
reserves
|
1,321
|
|
1,054
|
|
|
|
|
|
|
Shareholders’ equity
|
16,377
|
|
13,671
|
|
|
|
|
|
|
Non-controlling
interests
|
(421)
|
|
(585)
|
|
|
|
|
|
|
TOTAL EQUITY
|
15,956
|
|
13,086
|
Statement of changes in equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share
capital
£m
|
|
Share
premium
£m
|
|
Retained
earnings
£m
|
|
Other
reserves
£m
|
|
Share-
holder’s
equity
£m
|
|
Non-
controlling
interests
£m
|
|
Total
equity
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2025
|
1,348
|
|
3,473
|
|
7,796
|
|
1,054
|
|
13,671
|
|
(585)
|
|
13,086
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the year
|
|
|
|
|
5,716
|
|
|
|
5,716
|
|
573
|
|
6,289
|
|
Other comprehensive income /(expense) for the year
|
|
|
|
|
323
|
|
188
|
|
511
|
|
(18)
|
|
493
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income/(expense) for the year
|
|
|
|
|
6,039
|
|
188
|
|
6,227
|
|
555
|
|
6,782
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(391)
|
|
(391)
|
|
Dividends
to shareholders
|
|
|
|
|
(2,564)
|
|
|
|
(2,564)
|
|
|
|
(2,564)
|
|
Realised after tax
profit/(losses) on disposal or liquidation of equity
investments
|
|
|
|
|
(66)
|
|
66
|
|
|
|
|
|
–
|
|
Share
of associates and joint ventures realised profit/(loss) on disposal
of equity investments
|
|
|
|
|
58
|
|
(58)
|
|
|
|
|
|
–
|
|
Shares
issued
|
1
|
|
14
|
|
|
|
|
|
15
|
|
|
|
15
|
|
Purchase
of treasury shares
|
|
|
|
|
(1,377)
|
|
|
|
(1,377)
|
|
|
|
(1,377)
|
|
Write-down
on shares held by ESOP Trusts
|
|
|
|
|
(467)
|
|
467
|
|
|
|
|
|
–
|
|
Shares
acquired by ESOP Trusts
|
|
|
11
|
|
385
|
|
(396)
|
|
|
|
|
|
–
|
|
Share-based
incentive plans
|
|
|
|
|
374
|
|
|
|
374
|
|
|
|
374
|
|
Tax on
share-based incentive plans
|
|
|
|
|
31
|
|
|
|
31
|
|
|
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 31 December 2025
|
1,349
|
|
3,498
|
|
10,209
|
|
1,321
|
|
16,377
|
|
(421)
|
|
15,956
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share
capital
£m
|
|
Share
premium
£m
|
|
Retained
earnings
£m
|
|
Other
reserves
£m
|
|
Share-
holder’s
equity
£m
|
|
Non-
controlling
interests
£m
|
|
Total
equity
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2024
|
1,348
|
|
3,451
|
|
7,239
|
|
1,309
|
|
13,347
|
|
(552)
|
|
12,795
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the year
|
|
|
|
|
2,575
|
|
|
|
2,575
|
|
376
|
|
2,951
|
|
Other comprehensive income /(expense) for the year
|
|
|
|
|
(83)
|
|
(86)
|
|
(169)
|
|
(4)
|
|
(173)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income/(expense) for the year
|
|
|
|
|
2,492
|
|
(86)
|
|
2,406
|
|
372
|
|
2,778
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(416)
|
|
(416)
|
|
Dividends
to shareholders
|
|
|
|
|
(2,444)
|
|
|
|
(2,444)
|
|
|
|
(2,444)
|
|
Deconsolidation
of former subsidiaries
|
|
|
|
|
|
|
|
|
|
|
(2)
|
|
(2)
|
|
Realised after tax
profit/(losses) on disposal or liquidation of equity
investments
|
|
|
|
|
14
|
|
(14)
|
|
|
|
|
|
–
|
|
Share
of associates and joint ventures realised profit/(loss) on disposal
of equity investments
|
|
|
|
|
52
|
|
(52)
|
|
|
|
|
|
–
|
|
Shares
issued
|
|
|
20
|
|
|
|
|
|
20
|
|
|
|
20
|
|
Write-down
of shares held by ESOP Trusts
|
|
|
|
|
(362)
|
|
362
|
|
|
|
|
|
–
|
|
Shares
acquired by ESOP Trusts
|
|
|
2
|
|
457
|
|
(459)
|
|
|
|
|
|
–
|
|
Share-based
incentive plans
|
|
|
|
|
344
|
|
|
|
344
|
|
|
|
344
|
|
Contributions from
non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
9
|
|
9
|
|
Changes
to non-controlling interest
|
|
|
|
|
|
|
|
|
|
|
4
|
|
4
|
|
Hedging
gain/(loss) after taxation transferred to non-financial
assets
|
|
|
|
|
|
|
(6)
|
|
(6)
|
|
|
|
(6)
|
|
Tax on
share-based incentive plans
|
|
|
|
|
4
|
|
|
|
4
|
|
|
|
4
|
|
At 31
December 2024
|
1,348
|
|
3,473
|
|
7,796
|
|
1,054
|
|
13,671
|
|
(585)
|
|
13,086
|
Cash flow statement year ended 31 December 2025
|
|
|
|
|
|
|
2025
£m
|
|
2024
£m
|
|
Profit after tax
|
6,289
|
|
2,951
|
|
Tax on
profits
|
1,112
|
|
526
|
|
Share
of after tax loss/(profit) of associates and joint
ventures
|
(1)
|
|
3
|
|
(Profit)/loss
on disposal of interest in associates and joint
ventures
|
–
|
|
(6)
|
|
Net
finance expense
|
532
|
|
547
|
|
Depreciation,
amortisation and other adjusting items
|
3,778
|
|
2,985
|
|
(Increase)/decrease
in working capital
|
(622)
|
|
(175)
|
|
Contingent
consideration paid
|
(1,330)
|
|
(1,235)
|
|
Increase/(decrease)
in other net liabilities (excluding contingent consideration
paid)
|
(815)
|
|
2,265
|
|
Cash generated from operations
|
8,943
|
|
7,861
|
|
Taxation
paid
|
(1,202)
|
|
(1,307)
|
|
Total net cash inflow/(outflow) from operating
activities
|
7,741
|
|
6,554
|
|
Cash flow from investing activities
|
|
|
|
|
Purchase
of property, plant and equipment
|
(1,348)
|
|
(1,399)
|
|
Proceeds
from sale of property, plant and equipment
|
24
|
|
65
|
|
Purchase
of intangible assets
|
(1,637)
|
|
(1,583)
|
|
Proceeds
from sale of intangible assets
|
115
|
|
131
|
|
Purchase
of equity investments
|
(92)
|
|
(103)
|
|
Proceeds
from sale of equity investments
|
189
|
|
2,356
|
|
Share
transactions with non-controlling interests
|
–
|
|
(1)
|
|
Purchase
of businesses, net of cash acquired
|
(1,692)
|
|
(805)
|
|
Investment
in joint ventures and associates
|
–
|
|
(43)
|
|
Contingent
consideration paid
|
(17)
|
|
(19)
|
|
Disposal
of businesses
|
(27)
|
|
(18)
|
|
Interest
received
|
154
|
|
138
|
|
(Increase)/decrease
in liquid investments
|
11
|
|
21
|
|
Dividends
from joint ventures and associates
|
67
|
|
15
|
|
Dividend
and distributions from investments
|
20
|
|
16
|
|
Total net cash inflow/(outflow) from investing
activities
|
(4,233)
|
|
(1,229)
|
|
Cash flow from financing activities
|
|
|
|
|
Issue
of share capital
|
15
|
|
20
|
|
Repayment
of long-term loans
|
(1,400)
|
|
(1,615)
|
|
Issue
of long-term notes
|
1,979
|
|
1,075
|
|
Net
increase/(decrease) in short-term loans
|
1,085
|
|
(811)
|
|
Increase
in other short-term loans
|
130
|
|
266
|
|
Repayment
of other short-term loans
|
(288)
|
|
(81)
|
|
Repayment
of lease liabilities
|
(241)
|
|
(226)
|
|
Interest
paid
|
(679)
|
|
(632)
|
|
Dividends
paid to shareholders
|
(2,564)
|
|
(2,444)
|
|
Purchase
of treasury shares
|
(1,377)
|
|
–
|
|
Distribution
to non-controlling interests
|
(391)
|
|
(416)
|
|
Contributions
from non-controlling interests
|
–
|
|
9
|
|
Other
financing items
|
46
|
|
129
|
|
Total net cash inflow/(outflow) from financing
activities
|
(3,685)
|
|
(4,726)
|
|
Increase/(decrease) in cash and bank overdrafts in the
year
|
(177)
|
|
599
|
|
Cash
and bank overdrafts at beginning of the year
|
3,403
|
|
2,858
|
|
Exchange
adjustments
|
(19)
|
|
(54)
|
|
Increase/(decrease)
in cash and bank overdrafts in the year
|
(177)
|
|
599
|
|
Cash and bank overdrafts at end of the year
|
3,207
|
|
3,403
|
|
Cash
and bank overdrafts at end of year comprise:
|
|
|
|
|
Cash and cash equivalents
|
3,397
|
|
3,870
|
|
Overdrafts
|
(190)
|
|
(467)
|
|
|
3,207
|
|
3,403
|
Sales tables
Specialty Medicines turnover – year ended 31 December
2025
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
HIV
|
7,687
|
8
|
11
|
|
5,312
|
11
|
14
|
|
1,558
|
4
|
3
|
|
817
|
2
|
6
|
|
Dolutegravir
products
|
5,648
|
1
|
3
|
|
3,567
|
1
|
4
|
|
1,336
|
2
|
–
|
|
745
|
–
|
3
|
|
Tivicay
|
1,323
|
(2)
|
–
|
|
801
|
3
|
6
|
|
237
|
(6)
|
(7)
|
|
285
|
(10)
|
(9)
|
|
Triumeq
|
991
|
(25)
|
(23)
|
|
728
|
(23)
|
(21)
|
|
153
|
(31)
|
(32)
|
|
110
|
(32)
|
(28)
|
|
Juluca
|
656
|
(4)
|
(2)
|
|
527
|
(3)
|
(1)
|
|
117
|
(8)
|
(9)
|
|
12
|
–
|
8
|
|
Dovato
|
2,678
|
20
|
22
|
|
1,511
|
19
|
23
|
|
829
|
16
|
15
|
|
338
|
32
|
37
|
|
Cabenuva
|
1,402
|
38
|
42
|
|
1,160
|
40
|
44
|
|
202
|
29
|
28
|
|
40
|
54
|
62
|
|
Apretude
|
439
|
57
|
62
|
|
432
|
60
|
64
|
|
–
|
–
|
–
|
|
7
|
(22)
|
(22)
|
|
Rukobia
|
169
|
5
|
8
|
|
150
|
1
|
4
|
|
10
|
25
|
25
|
|
9
|
>100
|
>100
|
|
Other
|
29
|
(22)
|
(16)
|
|
3
|
(50)
|
(50)
|
|
10
|
(38)
|
(31)
|
|
16
|
7
|
13
|
|
Respiratory,
Immunology & Inflammation
|
3,810
|
15
|
18
|
|
2,505
|
14
|
17
|
|
638
|
16
|
15
|
|
667
|
19
|
25
|
|
Nucala
|
2,008
|
13
|
15
|
|
1,040
|
7
|
10
|
|
521
|
16
|
15
|
|
447
|
23
|
28
|
|
Benlysta
|
1,773
|
19
|
22
|
|
1,464
|
20
|
23
|
|
134
|
17
|
15
|
|
175
|
14
|
20
|
|
Other
|
29
|
(22)
|
(19)
|
|
1
|
(91)
|
>(100)
|
|
(17)
|
(6)
|
(6)
|
|
45
|
7
|
14
|
|
Oncology
|
1,977
|
40
|
43
|
|
1,364
|
36
|
40
|
|
469
|
39
|
38
|
|
144
|
97
|
>100
|
|
Jemperli
|
861
|
84
|
89
|
|
647
|
69
|
74
|
|
159
|
>100
|
>100
|
|
55
|
>100
|
>100
|
|
Zejula
|
557
|
(6)
|
(4)
|
|
292
|
(4)
|
(2)
|
|
215
|
(7)
|
(8)
|
|
50
|
(12)
|
(2)
|
|
Blenrep
|
17
|
>100
|
>100
|
|
8
|
>100
|
>100
|
|
9
|
80
|
80
|
|
–
|
–
|
–
|
|
Ojjaara/Omjjara
|
554
|
57
|
60
|
|
417
|
32
|
36
|
|
98
|
>100
|
>100
|
|
39
|
>100
|
>100
|
|
Other
|
(12)
|
>(100)
|
>(100)
|
|
–
|
–
|
–
|
|
(12)
|
>(100)
|
>(100)
|
|
–
|
–
|
–
|
|
Specialty Medicines
|
13,474
|
14
|
17
|
|
9,181
|
15
|
18
|
|
2,665
|
12
|
11
|
|
1,628
|
14
|
18
|
Specialty Medicines turnover – three months ended 31 December
2025
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
HIV
|
2,149
|
9
|
11
|
|
1,545
|
11
|
15
|
|
425
|
10
|
5
|
|
179
|
(3)
|
(1)
|
|
Dolutegravir
products
|
1,556
|
3
|
4
|
|
1,031
|
1
|
5
|
|
363
|
8
|
4
|
|
162
|
(2)
|
–
|
|
Tivicay
|
346
|
1
|
2
|
|
235
|
9
|
14
|
|
63
|
2
|
(2)
|
|
48
|
(27)
|
(32)
|
|
Triumeq
|
269
|
(22)
|
(21)
|
|
209
|
(20)
|
(17)
|
|
36
|
(28)
|
(32)
|
|
24
|
(33)
|
(33)
|
|
Juluca
|
183
|
(3)
|
(1)
|
|
150
|
(3)
|
(1)
|
|
30
|
(6)
|
(9)
|
|
3
|
50
|
>100
|
|
Dovato
|
758
|
19
|
21
|
|
437
|
13
|
17
|
|
234
|
23
|
17
|
|
87
|
43
|
51
|
|
Cabenuva
|
410
|
32
|
35
|
|
343
|
34
|
39
|
|
55
|
20
|
13
|
|
12
|
50
|
37
|
|
Apretude
|
129
|
54
|
60
|
|
128
|
58
|
63
|
|
–
|
–
|
–
|
|
1
|
(67)
|
(33)
|
|
Rukobia
|
46
|
(10)
|
(6)
|
|
42
|
(7)
|
–
|
|
3
|
50
|
50
|
|
1
|
(75)
|
(100)
|
|
Other
|
8
|
–
|
25
|
|
1
|
>100
|
82
|
|
4
|
–
|
25
|
|
3
|
(25)
|
25
|
|
Respiratory,
Immunology & Inflammation
|
1,089
|
18
|
21
|
|
752
|
19
|
23
|
|
169
|
21
|
15
|
|
168
|
14
|
19
|
|
Nucala
|
567
|
17
|
19
|
|
312
|
16
|
21
|
|
136
|
18
|
13
|
|
119
|
18
|
22
|
|
Benlysta
|
516
|
22
|
26
|
|
439
|
23
|
28
|
|
36
|
20
|
13
|
|
41
|
11
|
16
|
|
Other
|
6
|
(58)
|
(58)
|
|
1
|
(89)
|
>(100)
|
|
(3)
|
36
|
36
|
|
8
|
(20)
|
–
|
|
Oncology
|
567
|
39
|
42
|
|
387
|
29
|
34
|
|
136
|
55
|
49
|
|
44
|
>100
|
>100
|
|
Jemperli
|
261
|
75
|
79
|
|
191
|
55
|
61
|
|
52
|
>100
|
>100
|
|
18
|
>100
|
>100
|
|
Zejula
|
138
|
(3)
|
(3)
|
|
76
|
4
|
8
|
|
51
|
(11)
|
(18)
|
|
11
|
(15)
|
–
|
|
Blenrep
|
13
|
>100
|
>100
|
|
8
|
>100
|
>100
|
|
5
|
>100
|
>100
|
|
–
|
–
|
–
|
|
Ojjaara/Omjjara
|
158
|
34
|
37
|
|
112
|
9
|
13
|
|
32
|
>100
|
>100
|
|
14
|
>100
|
>100
|
|
Other
|
(3)
|
–
|
33
|
|
–
|
–
|
–
|
|
(4)
|
(33)
|
–
|
|
1
|
>100
|
>100
|
|
Specialty Medicines
|
3,805
|
15
|
18
|
|
2,684
|
15
|
19
|
|
730
|
19
|
14
|
|
391
|
11
|
15
|
Vaccines turnover – year ended 31 December 2025
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
Shingles
|
3,558
|
6
|
8
|
|
1,200
|
(20)
|
(17)
|
|
1,317
|
44
|
42
|
|
1,041
|
9
|
13
|
|
Shingrix
|
3,558
|
6
|
8
|
|
1,200
|
(20)
|
(17)
|
|
1,317
|
44
|
42
|
|
1,041
|
9
|
13
|
|
Meningitis
|
1,583
|
10
|
12
|
|
669
|
1
|
4
|
|
603
|
25
|
24
|
|
311
|
7
|
13
|
|
Bexsero
|
1,150
|
14
|
16
|
|
358
|
(2)
|
1
|
|
593
|
26
|
24
|
|
199
|
14
|
24
|
|
Menveo
|
402
|
4
|
6
|
|
303
|
2
|
5
|
|
8
|
14
|
14
|
|
91
|
11
|
12
|
|
Penmenvy
|
8
|
–
|
–
|
|
8
|
–
|
–
|
|
–
|
–
|
–
|
|
–
|
–
|
–
|
|
Other
|
23
|
(43)
|
(40)
|
|
–
|
–
|
–
|
|
2
|
(50)
|
(50)
|
|
21
|
(42)
|
(39)
|
|
RSV
|
593
|
1
|
2
|
|
301
|
(40)
|
(39)
|
|
218
|
>100
|
>100
|
|
74
|
37
|
44
|
|
Arexvy
|
593
|
1
|
2
|
|
301
|
(40)
|
(39)
|
|
218
|
>100
|
>100
|
|
74
|
37
|
44
|
|
Influenza
|
303
|
(26)
|
(24)
|
|
212
|
(33)
|
(31)
|
|
21
|
(32)
|
(32)
|
|
70
|
17
|
22
|
|
Fluarix, FluLaval
|
303
|
(26)
|
(24)
|
|
212
|
(33)
|
(31)
|
|
21
|
(32)
|
(32)
|
|
70
|
17
|
22
|
|
Established Vaccines
|
3,120
|
(7)
|
(5)
|
|
1,268
|
(3)
|
(1)
|
|
718
|
(1)
|
(2)
|
|
1,134
|
(13)
|
(11)
|
|
Boostrix
|
654
|
(4)
|
(2)
|
|
400
|
(7)
|
(4)
|
|
142
|
4
|
2
|
|
112
|
(3)
|
3
|
|
Cervarix
|
23
|
(68)
|
(68)
|
|
–
|
–
|
–
|
|
8
|
(43)
|
(43)
|
|
15
|
(74)
|
(74)
|
|
Hepatitis
|
643
|
(7)
|
(5)
|
|
321
|
(17)
|
(15)
|
|
202
|
6
|
5
|
|
120
|
6
|
12
|
|
Infanrix, Pediarix
|
519
|
1
|
4
|
|
295
|
11
|
14
|
|
115
|
(4)
|
(5)
|
|
109
|
(14)
|
(9)
|
|
Priorix, Priorix Tetra, Varilrix
|
425
|
32
|
33
|
|
60
|
54
|
56
|
|
134
|
10
|
9
|
|
231
|
43
|
46
|
|
Rotarix
|
546
|
(7)
|
(5)
|
|
160
|
(7)
|
(4)
|
|
128
|
4
|
3
|
|
258
|
(12)
|
(9)
|
|
Synflorix
|
159
|
(30)
|
(29)
|
|
–
|
–
|
–
|
|
3
|
(73)
|
(73)
|
|
156
|
(27)
|
(27)
|
|
Other
|
151
|
(39)
|
(39)
|
|
32
|
>100
|
>100
|
|
(14)
|
>(100)
|
>(100)
|
|
133
|
(41)
|
(41)
|
|
Vaccines
|
9,157
|
–
|
2
|
|
3,650
|
(15)
|
(12)
|
|
2,877
|
32
|
30
|
|
2,630
|
(1)
|
2
|
Vaccines turnover – three months ended 31 December
2025
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
Shingles
|
1,008
|
19
|
20
|
|
331
|
(20)
|
(17)
|
|
370
|
48
|
42
|
|
307
|
69
|
73
|
|
Shingrix
|
1,008
|
19
|
20
|
|
331
|
(20)
|
(17)
|
|
370
|
48
|
42
|
|
307
|
69
|
73
|
|
Meningitis
|
313
|
6
|
6
|
|
87
|
6
|
11
|
|
154
|
7
|
2
|
|
72
|
4
|
7
|
|
Bexsero
|
250
|
10
|
9
|
|
48
|
23
|
31
|
|
152
|
8
|
3
|
|
50
|
6
|
11
|
|
Menveo
|
53
|
6
|
8
|
|
36
|
(16)
|
(12)
|
|
2
|
–
|
–
|
|
15
|
>100
|
>100
|
|
Penmenvy
|
3
|
–
|
–
|
|
3
|
–
|
–
|
|
–
|
–
|
–
|
|
–
|
–
|
–
|
|
Other
|
7
|
(61)
|
(56)
|
|
–
|
–
|
–
|
|
–
|
(100)
|
(100)
|
|
7
|
(59)
|
(53)
|
|
RSV
|
198
|
25
|
25
|
|
71
|
(39)
|
(36)
|
|
106
|
>100
|
>100
|
|
21
|
40
|
33
|
|
Arexvy
|
198
|
25
|
25
|
|
71
|
(39)
|
(36)
|
|
106
|
>100
|
>100
|
|
21
|
40
|
33
|
|
Influenza
|
80
|
(24)
|
(21)
|
|
53
|
(27)
|
(23)
|
|
3
|
(82)
|
(82)
|
|
24
|
60
|
60
|
|
Fluarix, FluLaval
|
80
|
(24)
|
(21)
|
|
53
|
(27)
|
(23)
|
|
3
|
(82)
|
(82)
|
|
24
|
60
|
60
|
|
Established Vaccines
|
694
|
(14)
|
(13)
|
|
240
|
(19)
|
(16)
|
|
199
|
11
|
5
|
|
255
|
(22)
|
(21)
|
|
Boostrix
|
150
|
1
|
3
|
|
88
|
(4)
|
(1)
|
|
32
|
(3)
|
(9)
|
|
30
|
25
|
33
|
|
Cervarix
|
8
|
33
|
50
|
|
–
|
–
|
–
|
|
1
|
(67)
|
(67)
|
|
7
|
>100
|
>100
|
|
Hepatitis
|
136
|
(20)
|
(19)
|
|
51
|
(46)
|
(41)
|
|
52
|
11
|
4
|
|
33
|
10
|
17
|
|
Infanrix, Pediarix
|
104
|
(15)
|
(13)
|
|
53
|
(10)
|
(7)
|
|
33
|
–
|
(3)
|
|
18
|
(40)
|
(37)
|
|
Priorix, Priorix Tetra, Varilrix
|
98
|
18
|
19
|
|
12
|
(8)
|
(8)
|
|
44
|
52
|
45
|
|
42
|
2
|
10
|
|
Rotarix
|
120
|
(23)
|
(22)
|
|
23
|
(34)
|
(29)
|
|
36
|
3
|
–
|
|
61
|
(29)
|
(29)
|
|
Synflorix
|
23
|
(67)
|
(70)
|
|
–
|
–
|
–
|
|
1
|
(75)
|
(75)
|
|
22
|
(66)
|
(69)
|
|
Other
|
55
|
10
|
2
|
|
13
|
>100
|
>100
|
|
–
|
>100
|
75
|
|
42
|
(14)
|
(18)
|
|
Vaccines
|
2,293
|
4
|
4
|
|
782
|
(21)
|
(17)
|
|
832
|
35
|
29
|
|
679
|
11
|
14
|
General Medicines turnover – year ended 31 December
2025
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
Respiratory
|
7,068
|
(2)
|
–
|
|
3,816
|
(1)
|
1
|
|
1,394
|
(2)
|
(3)
|
|
1,858
|
(3)
|
1
|
|
Anoro Ellipta
|
542
|
(5)
|
(4)
|
|
207
|
(20)
|
(17)
|
|
235
|
6
|
5
|
|
100
|
8
|
13
|
|
Flixotide/Flovent
|
421
|
(20)
|
(18)
|
|
277
|
(23)
|
(21)
|
|
63
|
(11)
|
(11)
|
|
81
|
(16)
|
(12)
|
|
Relvar/Breo Ellipta
|
1,017
|
(5)
|
(3)
|
|
367
|
(7)
|
(4)
|
|
352
|
(5)
|
(6)
|
|
298
|
(1)
|
3
|
|
Seretide/Advair
|
858
|
(19)
|
(17)
|
|
267
|
(27)
|
(24)
|
|
184
|
(16)
|
(16)
|
|
407
|
(14)
|
(11)
|
|
Trelegy Ellipta
|
2,986
|
11
|
13
|
|
2,183
|
10
|
13
|
|
335
|
7
|
6
|
|
468
|
16
|
21
|
|
Ventolin
|
703
|
–
|
3
|
|
365
|
1
|
4
|
|
120
|
12
|
10
|
|
218
|
(6)
|
(1)
|
|
Other
Respiratory
|
541
|
(8)
|
(5)
|
|
150
|
2
|
5
|
|
105
|
(13)
|
(14)
|
|
286
|
(10)
|
(7)
|
|
Other General Medicines
|
2,968
|
(8)
|
(4)
|
|
212
|
(9)
|
(6)
|
|
597
|
(12)
|
(13)
|
|
2,159
|
(6)
|
(2)
|
|
Augmentin
|
602
|
(5)
|
(1)
|
|
–
|
–
|
–
|
|
172
|
(7)
|
(8)
|
|
430
|
(4)
|
2
|
|
Lamictal
|
391
|
(3)
|
(1)
|
|
159
|
(2)
|
–
|
|
102
|
(4)
|
(5)
|
|
130
|
(4)
|
–
|
|
Other
General Medicines
|
1,975
|
(9)
|
(6)
|
|
53
|
(25)
|
(21)
|
|
323
|
(16)
|
(17)
|
|
1,599
|
(7)
|
(3)
|
|
General Medicines
|
10,036
|
(4)
|
(1)
|
|
4,028
|
(2)
|
1
|
|
1,991
|
(5)
|
(6)
|
|
4,017
|
(5)
|
–
|
General Medicines turnover – three months ended 31 December
2025
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
Respiratory
|
1,785
|
(1)
|
1
|
|
930
|
(3)
|
1
|
|
357
|
(3)
|
(7)
|
|
498
|
4
|
7
|
|
Anoro Ellipta
|
132
|
(10)
|
(10)
|
|
44
|
(33)
|
(30)
|
|
62
|
9
|
5
|
|
26
|
8
|
8
|
|
Flixotide/Flovent
|
113
|
(21)
|
(19)
|
|
77
|
(23)
|
(21)
|
|
16
|
(20)
|
(20)
|
|
20
|
(13)
|
(9)
|
|
Relvar/Breo Ellipta
|
229
|
(17)
|
(16)
|
|
63
|
(32)
|
(29)
|
|
86
|
(11)
|
(14)
|
|
80
|
(6)
|
(4)
|
|
Seretide/Advair
|
243
|
(6)
|
(4)
|
|
89
|
(2)
|
1
|
|
45
|
(15)
|
(17)
|
|
109
|
(5)
|
(3)
|
|
Trelegy Ellipta
|
740
|
11
|
14
|
|
526
|
11
|
15
|
|
88
|
7
|
2
|
|
126
|
12
|
17
|
|
Ventolin
|
196
|
15
|
18
|
|
99
|
15
|
21
|
|
34
|
10
|
3
|
|
63
|
19
|
21
|
|
Other
Respiratory
|
132
|
(8)
|
(6)
|
|
32
|
(32)
|
(28)
|
|
26
|
(7)
|
(14)
|
|
74
|
9
|
12
|
|
Other General Medicines
|
735
|
(8)
|
(6)
|
|
47
|
(15)
|
(11)
|
|
148
|
(4)
|
(8)
|
|
540
|
(9)
|
(5)
|
|
Augmentin
|
158
|
(2)
|
1
|
|
–
|
–
|
–
|
|
43
|
(9)
|
(15)
|
|
115
|
1
|
7
|
|
Lamictal
|
91
|
(10)
|
(8)
|
|
32
|
(20)
|
(15)
|
|
26
|
4
|
–
|
|
33
|
(8)
|
(6)
|
|
Other
General Medicines
|
486
|
(10)
|
(7)
|
|
15
|
–
|
–
|
|
79
|
(3)
|
(7)
|
|
392
|
(11)
|
(7)
|
|
General Medicines
|
2,520
|
(3)
|
(1)
|
|
977
|
(3)
|
–
|
|
505
|
(3)
|
(7)
|
|
1,038
|
(3)
|
–
|
Commercial Operations turnover
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
Year
ended 31 December 2025
|
32,667
|
4
|
7
|
|
16,859
|
3
|
6
|
|
7,533
|
13
|
12
|
|
8,275
|
(1)
|
4
|
|
Three
months ended 31 December 2025
|
8,618
|
6
|
8
|
|
4,443
|
3
|
7
|
|
2,067
|
18
|
13
|
|
2,108
|
4
|
7
|
Segment information
Operating
segments are reported based on the financial information provided
to the Chief Executive Officer and the responsibilities of the
Executive Committee (formerly known as the GSK Leadership Team).
GSK reports results under two segments: Commercial Operations and
Total R&D. Members of the Executive Committee are responsible
for each segment.
R&D
investment is essential for the sustainability of the business.
However, for segment reporting the Commercial operating profits
exclude allocations of globally funded R&D.
The
Total R&D segment is the responsibility of the Chief Scientific
Officer and is reported as a separate segment. The operating costs
of this segment includes R&D activities across Specialty
Medicines, including HIV and Vaccines. It includes R&D and some
SG&A costs relating to regulatory and other
functions.
The
Group’s management reporting process allocates intra-Group
profit on a product sale to the market in which that sale is
recorded, and the profit analyses below have been presented on that
basis.
Adjusting
items reconciling segment profit and operating profit comprise
items not specifically allocated to segment profit. These include
impairment and amortisation of intangible assets (excluding
computer software and capitalised development costs), major
restructuring costs, which include impairments of tangible assets
and computer software, transaction-related adjustments related to
significant acquisitions, proceeds and costs of disposals of
associates, products and businesses, Significant legal charges and
expenses on the settlement of litigation and government
investigations, other operating income other than royalty income,
and other items including amounts reclassified from the foreign
currency translation reserve to the income statement upon the
liquidation of a subsidiary where the amount exceeds £25
million.
Turnover by segment
|
|
2025
£m
|
|
2024
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations (total turnover)
|
32,667
|
|
31,376
|
|
4
|
|
7
|
Operating profit by segment
|
|
2025
£m
|
|
2024
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
16,260
|
|
15,335
|
|
6
|
|
10
|
|
Research
and Development
|
(6,251)
|
|
(5,845)
|
|
7
|
|
9
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
10,009
|
|
9,490
|
|
5
|
|
10
|
|
Corporate
and other unallocated costs
|
(226)
|
|
(342)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Core
operating profit
|
9,783
|
|
9,148
|
|
7
|
|
11
|
|
Adjusting
items
|
(1,851)
|
|
(5,127)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
7,932
|
|
4,021
|
|
97
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
169
|
|
122
|
|
|
|
|
|
Finance
costs
|
(701)
|
|
(669)
|
|
|
|
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
1
|
|
(3)
|
|
|
|
|
|
Profit/(loss)
on disposal of associates and joint ventures
|
–
|
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
7,401
|
|
3,477
|
|
>100
|
|
>100
|
Commercial
Operations Core operating profit of £16,260 million growth in
the full year was driven by higher turnover, favourable product mix
and royalty income including from an IP settlement, partly offset
by increased investment in new asset launches and growth assets,
and adverse pricing impacts. In addition, in Q4 2025 productivity
programmes and supply chain charges totalled £300
million.
The
R&D segment operating expense of £6,251 million grew in
the full year primarily reflecting progression across the
portfolio. In Oncology, this included acceleration in work on ADCs
(B7-H3 and B7-H4) and IDRX-42, the GIST treatment acquired in Q1
2025. In Specialty Medicines, increased investment was driven by
efimosfermin acquired from Boston Pharmaceuticals in Q3 2025 and
bepirovirsen, as well as progression of ULA treatment and PrEP
programmes, notably Q4M and Q6M. Growth was partly offset by lower
spend on depemokimab following filing in Q4 2024. Investment also
increased on clinical trial programmes associated with the
pneumococcal MAPS and mRNA seasonal flu.
Turnover by segment
|
|
Q4 2025
£m
|
|
Q4
2024
£m
|
|
Growth
AER%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations (total turnover)
|
8,618
|
|
8,117
|
|
6
|
|
8
|
Operating profit by segment
|
|
Q4 2025
£m
|
|
Q4
2024
£m
|
|
Growth
AER%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
3,720
|
|
3,323
|
|
12
|
|
16
|
|
Research
and Development
|
(1,942)
|
|
(1,790)
|
|
8
|
|
10
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
1,778
|
|
1,533
|
|
16
|
|
22
|
|
Corporate
and other unallocated costs
|
(144)
|
|
(102)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Core
operating profit
|
1,634
|
|
1,431
|
|
14
|
|
18
|
|
Adjusting
items
|
(534)
|
|
(735)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
1,100
|
|
696
|
|
58
|
|
65
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
39
|
|
34
|
|
|
|
|
|
Finance
costs
|
(188)
|
|
(173)
|
|
|
|
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(1)
|
|
–
|
|
|
|
|
|
Profit/(loss)
on disposal of associates and joint ventures
|
–
|
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
950
|
|
563
|
|
69
|
|
78
|
Commercial
Operations Core operating profit of £3,720 million increased
in the quarter driven by higher turnover, favourable product mix
and royalty income, partly offset by increased investment in new
asset launches and growth assets, and adverse pricing impacts. In
addition, in the quarter productivity programmes and supply chain
charges totalled £300 million.
The
R&D segment operating expense of £1,942 million grew in
the quarter primarily reflecting progression across the portfolio.
In Oncology, this included acceleration in work on ADCs (B7-H3 and
B7-H4) and IDRX-42, the GIST treatment acquired in Q1 2025. In
Specialty Medicines, increased investment was driven by
efimosfermin acquired from Boston Pharmaceuticals in Q3 2025, and
bepirovirsen, as well as progression of ULA treatment and PrEP
programmes, notably Q4M and Q6M. Investment also increased on
clinical trial programmes associated with the pneumococcal MAPS and
mRNA seasonal flu.
Legal matters
The
Group is involved in significant legal and administrative
proceedings, principally product liability, intellectual property,
tax, anti-trust, consumer fraud and governmental investigations,
which are more fully described in the ‘Legal
Proceedings’ note in the Annual Report 2024. At 31 December
2025, the Group’s aggregate provision for legal and other
disputes (not including tax matters described on page 10) was
£210 million (31 December 2024: £1,446
million).
The
Group may become involved in significant legal proceedings in
respect of which it is not possible to meaningfully assess whether
the outcome will result in a probable outflow, or to quantify or
reliably estimate the liability, if any, that could result from
ultimate resolution of the proceedings. In these cases, the Group
would provide appropriate disclosures about such cases, but no
provision would be made.
The
ultimate liability for legal claims may vary from the amounts
provided and is dependent upon the outcome of litigation
proceedings, investigations and possible settlement negotiations.
The Group’s position could change over time, and, therefore,
there can be no assurance that any losses that result from the
outcome of any legal proceedings will not exceed by a material
amount the amount of the provisions reported in the Group’s
financial accounts.
Significant
legal developments since the date of the Q3 2025
results:
Product Liability
Zantac
As
previously disclosed, the vast majority of the remaining cases have
been resolved or dismissed such that 13 state court cases remain.
GSK has recently resolved the Mayor & City of Baltimore action
as well as the New Mexico Attorney General lawsuit.
In
Delaware, following the Supreme Court’s reversal of the lower
court’s decision on admissibility of expert opinions, the
defendants filed a motion for summary judgment. Plaintiffs filed a
motion to allow supplemental expert disclosures. A hearing on both
motions was held on 23 October 2025. On 1 December 2025, the
Delaware Superior Court issued its ruling denying Plaintiffs’
motion for supplemental expert disclosures. The Court requested
additional summary judgment briefing as to which Plaintiffs should
be bound by that ruling. Briefing on that issue concluded on 30
January 2026.
As
previously disclosed, approximately 14,000 product liability cases
were dismissed following the grant of defendants’ Daubert
motions in December 2022 in the Federal MDL proceeding. These are
now on appeal by the plaintiffs to the United States Court of
Appeals for the Eleventh Circuit, along with appeals in the medical
monitoring and consumer class action cases. Oral argument was held
on 10 October 2025. A decision is expected in the first half of
2026.
Avandia
On 22
May 2025, the district court granted the third-party payor
plaintiffs’ motion for class certification, allowing them to
proceed with their claims as a class action. GSK filed a Rule 23(f)
petition with the Third Circuit seeking permission to appeal the
class certification order, which was granted on 7 July 2025.
Briefing is complete, and oral argument has been scheduled for 26
February 2026. The trial court has stayed the proceedings pending
the outcome of the appeal.
Commercial and corporate
Tesaro, Inc. v. AnaptysBio
On 20
November 2025, GSK subsidiary, Tesaro, Inc., initiated litigation
against AnaptysBio, Inc. in the Delaware Chancery Court. This
action seeks a declaration that Tesaro was not in breach and that
AnaptysBio engaged in conduct that was in anticipatory breach of
the parties’ collaboration agreement regarding the oncology
treatment Jemperli
(dostarlimab). Tesaro initiated this litigation following
allegations made by AnaptysBio that Tesaro breached the
collaboration agreement, entitling AnaptysBio to a reversion of
rights to dostarlimab. AnaptysBio filed a lawsuit against
Tesaro/GSK on the same day, in the same court, seeking a
declaration that Tesaro breached the agreement and that GSK
tortiously interfered with the agreement by inducing Tesaro’s
alleged breaches. Trial is currently set for 14-17 July 2026.
AnaptysBio filed a partial motion to dismiss Tesaro’s
anticipatory breach of contract claim which will be heard by the
court on 4 March 2026. GSK and Tesaro intend to vigorously defend
against AnaptysBio’s allegations.
Intellectual Property
Breo
In
August 2025, GSK received a paragraph IV letter from Transpire Bio
Inc. (“Transpire”) relating to Breo. On 25 September 2025, GSK filed a
patent and trademark infringement suit against Transpire in the
United States District Court for the Southern District of Florida
alleging Transpire’s proposed generic of Breo infringes GSK patents and trade
dress. The court has set a trial date for 2 November
2026.
Trelegy
On 22
January 2026, GSK received a paragraph IV letter from Transpire
relating to Trelegy. GSK is
currently assessing the letter and considering its options. Under
the Hatch-Waxman Act, companies who receive such letters have 45
days to bring a lawsuit against the generic
manufacturer.
Returns to
shareholders
Quarterly dividends
The
Board has declared a fourth interim dividend for Q4 2025 of 18p per
share (Q4 2024: 16p per share).
Dividends
remain an essential component of total shareholder return and GSK
recognises the importance of dividends to shareholders. On 23 June
2021, at the GSK Investor Update, GSK set out that from 2022 a
progressive dividend policy will be implemented guided by a 40 to
60 per cent pay-out ratio through the investment cycle. Consistent
with this, and reflecting strong performance in 2025, GSK has
declared an increased dividend of 18p for Q4 2025 and 66p per share
for full year 2025. The expected dividend for 2026 is 70p per
share. In setting its dividend policy, GSK considers the capital
allocation priorities of the Group and its investment strategy for
growth alongside the sustainability of the dividend.
|
|
|
|
|
|
|
|
|
|
Dividend dates
|
Ex-dividend date
(Ordinary shares)
|
|
Ex-dividend date
(ADRs)
|
|
Record date
|
|
Payment date
|
|
Q4
2025
|
19
February 2026
|
|
20
February 2026
|
|
20
February 2026
|
|
9 April
2026
|
Ordinary
shareholders may participate in the dividend reinvestment plan
(DRIP). The last date for DRIP elections is 17 March 2026. The
equivalent interim dividend receivable by ADR holders will be
calculated based on the exchange rate on 7 April 2026. An annual
fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by
the Depositary.
|
|
|
|
|
|
|
|
|
Paid/
Payable
|
|
Pence
per
share
|
|
£m
|
|
2025
|
|
|
|
|
|
|
First
interim
|
10 July
2025
|
|
16
|
|
650
|
|
Second
interim
|
9
October 2025
|
|
16
|
|
646
|
|
Third
interim
|
8
January 2026
|
|
16
|
|
643
|
|
Fourth
interim
|
9 April
2026
|
|
18
|
|
722
|
|
|
|
|
66
|
|
2,661
|
|
|
|
|
|
|
|
|
2024
|
|
|
|
|
|
|
First
interim
|
11 July
2024
|
|
15
|
|
612
|
|
Second
interim
|
10
October 2024
|
|
15
|
|
612
|
|
Third
interim
|
9
January 2025
|
|
15
|
|
612
|
|
Fourth
interim
|
10
April 2025
|
|
16
|
|
656
|
|
|
|
|
61
|
|
2,492
|
Share capital in issue
At 31
December 2025, 4,013 million shares (2024: 4,081 million) were in
free issue (excluding Treasury shares and shares held by the ESOP
Trusts). The Company issued 1.1 million shares under employee share
schemes in the year for net proceeds of £15 million (2024:
£20 million).
On 5
February 2025, GSK announced a £2 billion share buyback
programme to be completed over an 18 month period. As at 31
December 2025, 93 million shares have been repurchased and are
being held as Treasury shares, at a cost of £1,377 million,
including transaction costs of £8 million.
At 31
December 2025, the Company held 240 million Treasury shares at a
cost of £3,948 million, of which 147 million shares at a cost
of £2,571 million were repurchased as part of previous share
buyback programmes, which has been deducted from retained
earnings.
At 31
December 2025, the ESOP Trusts held 62.8 million shares, of which
62.2 million were held for the future exercise of share options and
share awards and 0.6 million were held for the Executive
Supplemental Savings plan. The carrying amount of
£282 million has been deducted from other reserves.
The market value of these shares was £1,147
million.
Weighted average number of shares
The
numbers of shares used in calculating basic and diluted earnings
per share are reconciled below:
|
|
|
|
|
|
|
|
|
|
|
2025
millions
|
|
2024
millions
|
|
Q4 2025
millions
|
|
Q4
2024
millions
|
|
Weighted
average number of shares – basic
|
4,051
|
|
4,077
|
|
4,019
|
|
4,081
|
|
Dilutive
effect of share options and share awards
|
66
|
|
65
|
|
67
|
|
64
|
|
Weighted
average number of shares – diluted
|
4,117
|
|
4,142
|
|
4,086
|
|
4,145
|
Additional
information
Accounting policies and basis of preparation
This
unaudited Results Announcement contains condensed financial
information for the year-end and three months ended 31 December
2025 and should be read in conjunction with the Annual Report 2024,
which was prepared in accordance with UK-adopted international
accounting standards in conformity with the requirements of the
Companies Act 2006 and the IFRS Accounting Standards as issued by
the International Accounting Standards Board (IASB). This Results
Announcement has been prepared applying consistent accounting
policies to those applied by the Group in the Annual Report 2024,
except for the adoption of the amended IFRS Accounting Standard as
set out below.
The
IASB’s amendments to IAS 21 The Effects of Changes in Foreign Exchange
Rates specify how an entity should assess whether a currency
is exchangeable into another currency, and which spot exchange rate
should be used when it is not. GSK has adopted these new
requirements for the reporting period beginning on 1 January 2025,
with no material impact on the Group’s financial
statements.
The
Group has not identified any changes to its key sources of
accounting judgements or estimations of uncertainty compared with
those disclosed in the Annual Report 2024.
This
Results Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The full Group accounts for 2024 were published
in the Annual Report 2024, which has been delivered to the
Registrar of Companies and on which the report of the independent
auditor was unqualified and did not contain a statement under
section 498 of the Companies Act 2006.
Exchange rates
GSK
operates in many countries and earns revenues and incurs costs in
many currencies. The results of the Group, as reported in Sterling,
are affected by movements in exchange rates between Sterling and
other currencies. Average exchange rates, as modified by specific
transaction rates for large transactions, prevailing during the
period, are used to translate the results and cash flows of
overseas subsidiaries, associates and joint ventures into Sterling.
Period-end rates are used to translate the net assets of those
entities. The currencies which most influenced these translations
and the relevant exchange rates were:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2025
|
|
2024
|
|
Q4 2025
|
|
Q4
2024
|
||
|
|
|
|
|
|
|
|
|
|
||
|
Average
rates:
|
|
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
|
1.31
|
|
1.28
|
|
1.33
|
|
1.27
|
|
|
|
Euro/£
|
|
1.17
|
|
1.18
|
|
1.14
|
|
1.20
|
|
|
|
Yen/£
|
|
198
|
|
193
|
|
206
|
|
195
|
|
|
|
|
|
|
|
|
|
|
||
|
Period-end
rates:
|
|
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
|
1.35
|
|
1.25
|
|
1.35
|
|
1.25
|
|
|
|
Euro/£
|
|
1.15
|
|
1.20
|
|
1.15
|
|
1.20
|
|
|
|
Yen/£
|
|
211
|
|
197
|
|
211
|
|
197
|
Contingent liabilities
There
were contingent liabilities at 31 December 2025 in respect of
arrangements entered into as part of the ordinary course of the
Group’s business. No material losses are expected to arise
from such contingent liabilities. Provision is made for the outcome
of legal and tax disputes where it is both probable that the Group
will suffer an outflow of funds and it is possible to make a
reliable estimate of that outflow. Descriptions of the significant
legal disputes to which the Group is a party are set out on page
36, and pages 287 to 290 of the 2024 Annual Report.
Net assets
The
book value of net assets increased by £2,870 million from
£13,086 million at 31 December 2024 to £15,956 million at
31 December 2025. This primarily reflected contribution from Total
comprehensive income for the period partly offset by dividends paid
to shareholders, shares repurchased under the share buyback
programme and associated transaction costs.
At 31
December 2025, the net surplus on the Group’s pension plans
was £229 million compared with a £103 million net deficit
at 31 December 2024. This movement from a net deficit to a net
surplus is primarily related to an increase in UK asset values, a
decrease to the UK inflation rate from 2.90% to 2.70%, and a $131
million contribution made to the US Cash Balance Plan during Q3
2025. This is partially offset by a decrease to the US discount
rate from 5.5% to 5.1%.
Assets
held for sale as at 31 December 2025 included the manufacturing
facility located in Rockville, Maryland. On 22 December 2025, GSK
entered into a definitive agreement with Samsung Biologics for the
sale of 100% of its equity investment in Human Genome Sciences,
principally including the Rockville site, with closing anticipated
towards the end of Q1 2026.
The
estimated present value of the potential redemption amount of the
Pfizer put option related to ViiV Healthcare, recorded in Other
payables in Current liabilities, was £822 million (31
December 2024: £915 million).
Contingent
consideration amounted to £6,733 million at 31 December 2025
(31 December 2024: £7,280 million) as follows:
|
|
|
|
|
|
|
Group
31 December
2025
£m
|
|
Group
31
December
2024
£m
|
|
|
|
|
|
|
Contingent
consideration estimated present value of amounts payable relating
to:
|
|
|
|
|
Former
Shionogi-ViiV Healthcare joint venture
|
5,433
|
|
6,061
|
|
Former
Novartis Vaccines business acquisition
|
651
|
|
575
|
|
Affinivax
acquisition
|
219
|
|
502
|
|
Aiolos
acquisition
|
132
|
|
130
|
|
BP
Asset IX Inc acquisition
|
231
|
|
–
|
|
Others
|
67
|
|
12
|
|
|
|
|
|
|
Contingent
consideration liability at end of the period
|
6,733
|
|
7,280
|
Of the
contingent consideration payable to Shionogi at 31 December 2025,
£1,194 million (31 December 2024: £1,127 million) is
expected to be paid within one year.
Movements
in contingent consideration are as follows:
|
|
|
|
|
|
2025
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
6,061
|
|
7,280
|
|
Additions
|
–
|
|
280
|
|
Remeasurement
through income statement and other movements
|
649
|
|
520
|
|
Cash
payments: operating cash flows
|
(1,277)
|
|
(1,330)
|
|
Cash
payments: investing activities
|
–
|
|
(17)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,433
|
|
6,733
|
|
|
|
|
|
|
2024
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,718
|
|
6,662
|
|
Additions
|
–
|
|
104
|
|
Remeasurement
through income statement and other movements
|
1,533
|
|
1,768
|
|
Cash
payments: operating cash flows
|
(1,190)
|
|
(1,235)
|
|
Cash
payments: investing activities
|
–
|
|
(19)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
6,061
|
|
7,280
|
|
|
|
The
liabilities for the Pfizer put option and the contingent
consideration at 31 December 2025 have been calculated based on the
period-end exchange rates, primarily US$1.35/£1 and
€1.15/£1. Sensitivity analyses for the Pfizer put option
and each of the largest contingent consideration liabilities are
set out below for the following scenarios:
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase/(decrease)
in financial liability and loss/(gain) in Income
statement
|
ViiV
Healthcare
put
option
£m
|
|
Shionogi-ViiV
Healthcare
contingent
consideration
£m
|
|
Novartis
Vaccines
contingent
consideration
£m
|
|
Affinivax
contingent
consideration
£m
|
|
BP
Asset IX contingent consideration
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
10%
increase in sales forecasts*
|
88
|
|
508
|
|
92
|
|
n/a
|
|
n/a
|
|
15%
increase in sales forecasts*
|
132
|
|
762
|
|
137
|
|
n/a
|
|
n/a
|
|
10%
decrease in sales forecasts*
|
(87)
|
|
(510)
|
|
(92)
|
|
n/a
|
|
n/a
|
|
15%
decrease in sales forecasts*
|
(131)
|
|
(764)
|
|
(137)
|
|
n/a
|
|
n/a
|
|
1%
increase in discount rate
|
(16)
|
|
(144)
|
|
(41)
|
|
(7)
|
|
(8)
|
|
1.5%
increase in discount rate
|
(24)
|
|
(213)
|
|
(59)
|
|
(10)
|
|
(12)
|
|
1%
decrease in discount rate
|
18
|
|
152
|
|
47
|
|
7
|
|
9
|
|
1.5%
decrease in discount rate
|
27
|
|
233
|
|
73
|
|
11
|
|
13
|
|
10 cent
appreciation of US Dollar
|
56
|
|
360
|
|
15
|
|
18
|
|
19
|
|
15 cent
appreciation of US Dollar
|
86
|
|
562
|
|
24
|
|
27
|
|
29
|
|
10 cent
depreciation of US Dollar
|
(47)
|
|
(311)
|
|
(13)
|
|
(15)
|
|
(16)
|
|
15 cent
depreciation of US Dollar
|
(68)
|
|
(451)
|
|
(19)
|
|
(22)
|
|
(23)
|
|
10 cent
appreciation of Euro
|
18
|
|
73
|
|
24
|
|
n/a
|
|
n/a
|
|
15 cent
appreciation of Euro
|
28
|
|
116
|
|
38
|
|
n/a
|
|
n/a
|
|
10 cent
depreciation of Euro
|
(14)
|
|
(61)
|
|
(20)
|
|
n/a
|
|
n/a
|
|
15 cent
depreciation of Euro
|
(21)
|
|
(91)
|
|
(29)
|
|
n/a
|
|
n/a
|
|
10%
increase in probability of milestone success
|
n/a
|
|
n/a
|
|
22
|
|
68
|
|
24
|
|
10%
decrease in probability of milestone success
|
n/a
|
|
n/a
|
|
(11)
|
|
(32)
|
|
(31)
|
|
|
|
|
*
|
The sales forecast is for ViiV Healthcare sales only in respect of
the ViiV Healthcare put option and the Shionogi-ViiV Healthcare
contingent consideration.
|
Business acquisitions
On 21
February 2025, GSK completed the acquisition of 100% of IDRx, Inc,
a Boston based, clinical stage biopharmaceutical company dedicated
to developing precision therapies for the treatment of
gastrointestinal stromal tumours (GIST). The acquisition includes a
lead molecule, IDRX-42, a highly selective investigational tyrosine
kinase inhibitor (TKI) that is designed to improve the outcomes for
patients with GIST. The consideration for the acquisition comprised
an upfront payment of US$1.1 billion (£840 million) as
adjusted for working capital acquired paid upon closing and up to
US$150 million (£119 million) as an additional
success-based regulatory milestone payment. The estimated fair
value of the contingent consideration payable was US$56 million
(£45 million). In addition, GSK will also be responsible for
success-based milestone payments as well as tiered royalties for
IDRX-42 owed to Merck KGaA, Darmstadt, Germany.
On 7th
July 2025, GSK completed the acquisition of 100% of BP Asset IX,
Inc. a subsidiary of Boston Pharmaceuticals which provides access
to efimosfermin alfa. Efimosfermin is a phase III-ready, potential
best-in-class, investigational speciality medicine to treat and
prevent progression of steatotic liver disease (SLD). The
consideration for the acquisition comprised an upfront payment of
US$1.2 billion (£906 million) as adjusted for working capital
acquired paid upon closing and up to US$800 million (£588
million) in certain success-based regulatory milestone payments.
The estimated fair value of the contingent consideration payable
was US$302 million (£222 million).
During
the period to 31st December 2025, no sales arising from the IDRx or
BP Asset IX's businesses were included in Group turnover and no
revenue is expected until regulatory approval is received on the
respective acquired assets.
GSK
continues to support the ongoing development of the acquired assets
and consequently these assets will be loss making until regulatory
approval on these assets is received. The development of these
assets has been integrated into the Group’s existing R&D
activities, so it is impracticable to quantify these development
costs or the impact on Total profit after taxation for the period
ended 31 December 2025.
Goodwill
of £315 million (£109 million for IDRx and £206
million for BP Asset IX) has been recognised. The goodwill
represents specific synergies available to GSK from the business
combinations. The goodwill has been allocated to the Group’s
R&D segment. None of the goodwill is expected to be deductible
for tax purposes.
The
fair values of the net assets acquired, including goodwill, are as
follows:
|
|
|
|
|
|
|
|
|
|
|
IDRx Inc
|
|
BP Asset IX
|
|
Total
|
|
|
|
£m
|
|
£m
|
|
£m
|
|
Net
assets acquired:
|
|
|
|
|
|
|
|
Intangible
assets
|
|
882
|
|
1,088
|
|
1,970
|
|
Cash
and cash equivalents
|
|
48
|
|
30
|
|
78
|
|
Other
net liabilities
|
|
(26)
|
|
(8)
|
|
(34)
|
|
Deferred
tax liabilities
|
|
(128)
|
|
(188)
|
|
(316)
|
|
|
|
776
|
|
922
|
|
1,698
|
|
Goodwill
|
|
109
|
|
206
|
|
315
|
|
Total
consideration
|
|
885
|
|
1,128
|
|
2,013
|
Of the
total £2 billion consideration (£0.9 billion for IDRx and
£1.1 billion for BP Asset IX), £267 million (£45
million for IDRx and £222 million for BP Asset IX) of the
contingent consideration recognised at acquisition was unpaid as at
31 December 2025. As at 31 December 2025, the present value of the
contingent consideration payable was £45 million for IDRx and
£231 million for BP Asset IX.
On 15
January 2025, GSK completed the acquisition of a Berlin based
private company, Cellphenomics GmbH, which has developed
proprietary capabilities in developing durable organoid models, for
a total cash consideration of up to €44 million
(approximately £37 million) of which €15 million
(£13 million) was unpaid as at 31 December 2025. The
acquisition is accounted for as a business combination but is not
considered a significant acquisition for the Group.
Net debt information
Reconciliation of cash flow to movements in net debt
|
|
|
|
|
|
|
2025
£m
|
|
2024
£m
|
|
Total
Net debt at beginning of the period
|
(13,095)
|
|
(15,040)
|
|
Increase/(decrease)
in cash and bank overdrafts
|
(177)
|
|
599
|
|
Increase/(decrease)
in liquid investments
|
(11)
|
|
(21)
|
|
Repayment
of long-term loans
|
1,400
|
|
1,615
|
|
Issue
of long-term notes
|
(1,979)
|
|
(1,075)
|
|
Net
decrease/(increase) in short-term loans
|
(1,085)
|
|
811
|
|
Increase
in other short-term loans
|
(130)
|
|
(266)
|
|
Repayment
of other short-term loans
|
288
|
|
81
|
|
Repayment
of lease liabilities
|
241
|
|
226
|
|
Net
debt of subsidiary undertakings acquired
|
(1)
|
|
–
|
|
Exchange
adjustments
|
241
|
|
117
|
|
Other
non-cash movements
|
(145)
|
|
(142)
|
|
Decrease/(increase)
in net debt
|
(1,358)
|
|
1,945
|
|
Total
Net debt at end of the period
|
(14,453)
|
|
(13,095)
|
Net debt analysis
|
|
31 December 2025
£m
|
|
31
December 2024
£m
|
|
Liquid
investments
|
9
|
|
21
|
|
Cash
and cash equivalents
|
3,397
|
|
3,870
|
|
Short-term
borrowings
|
(3,012)
|
|
(2,349)
|
|
Long-term
borrowings
|
(14,708)
|
|
(14,637)
|
|
Liabilities
relating to assets held for sale
|
(139)
|
|
–
|
|
Total
Net debt at the end of the period
|
(14,453)
|
|
(13,095)
|
Free cash flow reconciliation
|
|
|
|
|
|
|
|
|
|
|
2025
£m
|
|
2024
£m
|
|
Q4 2025
£m
|
|
Q4
2024
£m
|
|
|
|
|
|
|
|
|
|
|
Net
cash inflow/(outflow) from operating activities
|
7,741
|
|
6,554
|
|
2,278
|
|
2,329
|
|
Purchase
of property, plant and equipment
|
(1,348)
|
|
(1,399)
|
|
(573)
|
|
(544)
|
|
Proceeds
from sale of property, plant and equipment
|
24
|
|
65
|
|
13
|
|
61
|
|
Purchase
of intangible assets
|
(1,637)
|
|
(1,583)
|
|
(452)
|
|
(591)
|
|
Proceeds
from disposals of intangible assets
|
115
|
|
131
|
|
3
|
|
5
|
|
Net
finance costs
|
(525)
|
|
(494)
|
|
(258)
|
|
(200)
|
|
Dividends
from associates and joint ventures
|
67
|
|
15
|
|
67
|
|
–
|
|
Contingent
consideration paid (reported in investing activities)
|
(17)
|
|
(19)
|
|
(6)
|
|
(8)
|
|
Distributions
to non-controlling interests
|
(391)
|
|
(416)
|
|
(112)
|
|
(128)
|
|
Contributions
from non-controlling interests
|
–
|
|
9
|
|
–
|
|
–
|
|
|
|
|
|
|
|
|
|
|
Free
cash inflow/(outflow)
|
4,029
|
|
2,863
|
|
960
|
|
924
|
|
|
|
Reconciliation of Total Operating Profit to Core
EBITDA
|
The
Total net debt/Core EBITDA ratio is disclosed solely for the
purpose of demonstrating a leverage ratio that is used by analysts,
investors and other stakeholders and which assesses the strength of
the balance sheet. It is calculated at the end of the financial
reporting year.
|
|
|
|
|
|
|
2025
£m
|
|
2024
£m
|
|
Total
Operating profit
|
7,932
|
|
4,021
|
|
Adjusting
items
|
1,851
|
|
5,127
|
|
Core
Operating profit
|
9,783
|
|
9,148
|
|
|
|
|
|
|
Including:
|
|
|
|
|
Share of Core after tax profit/(loss) of associates and joint
ventures
|
(10)
|
|
(3)
|
|
Excluding:
|
|
|
|
|
Core depreciation
|
1,055
|
|
1,096
|
|
Core amortisation
|
450
|
|
452
|
|
|
|
|
|
|
Core
EBITDA
|
11,278
|
|
10,693
|
Total Net debt to Core EBITDA ratio
|
|
|
|
|
|
|
2025
£m
|
|
2024
£m
|
|
Total
Net debt
|
14,453
|
|
13,095
|
|
Core
EBITDA
|
11,278
|
|
10,693
|
|
Total
Net debt to Core EBITDA ratio
|
1.3
|
|
1.2
|
Post balance sheet events
On 19
January 2026, GSK reached agreement with Pfizer and Shionogi for
the 11.7% economic interest in ViiV Healthcare currently held by
Pfizer to be replaced with an investment by Shionogi. As a result
of this transaction, Shionogi will increase its economic interest
to 21.7% and GSK will maintain its 78.3% economic interest. Under
the terms of the agreement, ViiV Healthcare will issue new shares
to Shionogi for consideration of $2.125 billion and cancel
Pfizer’s holding in ViiV Healthcare for a consideration of
$1.875 billion. Additionally, GSK will receive a special dividend
of $0.250 billion (payable in GBP). Completion of the transaction
is subject to certain regulatory clearances in relevant markets and
is expected to occur during Q1 2026. On completion, GSK will
extinguish the Pfizer put option liability through retained
earnings. The liability will be remeasured immediately prior to
completion, on the same methodology as at 31 December 2025, with
any change in the value of the liability recognised as an adjusting
item through other operating income/(expense).
On 19
January 2026, GSK entered into a definitive agreement to acquire
RAPT Therapeutics (RAPT), a California-based, clinical-stage
biopharmaceutical company dedicated to developing novel therapies
for patients living with inflammatory and immunologic diseases. The
acquisition includes ozureprubart, a long-acting
anti-immunoglobulin E (IgE) monoclonal antibody, currently in phase
IIb clinical development for prophylactic protection against food
allergens. Under the terms of the agreement, GSK’s subsidiary
has commenced a tender offer to acquire all outstanding shares of
RAPT common stock for $58.00 per share in cash at closing for an
estimated aggregate equity value of $2.2 billion. Net of cash
acquired, GSK's estimated upfront investment is $1.9 billion. The
transaction is expected to close in Q1 2026 and is subject to
customary closing conditions, including the tender of a majority of
RAPT's outstanding shares of common stock in the tender offer and
expiration or termination of the applicable waiting period under
the Hart-Scott-Rodino Act in the US.
Related party transactions
There
were no material related party transactions entered into and there
have been no material changes to the related party transactions
disclosed on page 258 of the 2024 Annual Report.
R&D
commentary
Pipeline overview
|
Medicines
and vaccines in phase III development (including major lifecycle
innovation or under regulatory review)
|
17
|
Respiratory, Immunology & Inflammation (6)
|
|
|
●
|
Nucala (anti-IL5 biologic) chronic obstructive pulmonary
disease (COPD)
|
||
|
●
|
Exdensur (ultra long-acting anti-IL5 biologic) asthma with
type 2 inflammation, eosinophilic granulomatosis with polyangiitis
(EGPA), chronic rhinosinusitis with nasal polyps (CRSwNP),
hyper-eosinophilic syndrome (HES), COPD
|
||
|
●
|
efimosfermin
(FGF21 analog) metabolic dysfunction-associated steatohepatitis
(MASH)
|
||
|
●
|
camlipixant
(P2X3 receptor antagonist) refractory chronic cough
|
||
|
●
|
Ventolin (salbutamol, Beta 2 adrenergic receptor agonist)
asthma
|
||
|
●
|
linerixibat
(IBATi) cholestatic pruritus in primary biliary
cholangitis
|
||
|
Oncology (5)
|
|||
|
●
|
Blenrep (anti-BCMA ADC) multiple myeloma
|
||
|
●
|
Jemperli (anti-PD-1) 1L endometrial cancer, colon cancer,
rectal cancer (ph II registrational), head and neck
cancer
|
||
|
●
|
Zejula (PARP inhibitor), glioblastoma
|
||
|
●
|
risvutatug
rezetecan (B7-H3 ADC) 2L extensive-stage small cell lung
cancer
|
||
|
●
|
velzatinib
(KIT inhibitor) gastro-intestinal tumours
|
||
|
Infectious Diseases (6)
|
|||
|
●
|
Arexvy (RSV vaccine) RSV, adults 18 years of age and
above
|
||
|
●
|
Blujepa (gepotidacin; bacterial topoisomerase inhibitor)
uncomplicated urinary tract infection and urogenital
gonorrhoea
|
||
|
●
|
bepirovirsen
(HBV ASO) chronic hepatitis B
|
||
|
●
|
Bexsero (meningococcal B vaccine) infants (US)
|
||
|
●
|
tebipenem
pivoxil (antibacterial carbapenem) complicated urinary tract
infection
|
||
|
●
|
GSK'116
(varicella vaccine) varicella new seed, individuals 12 months of
age and older
|
||
|
Total
medicines and vaccines in all phases of clinical
development
|
58
|
|
|
|
Total
projects in clinical development (inclusive of all phases and
indications)
|
79
|
|
|
Therapy area updates
The
following provides updates on key medicines and vaccines by therapy
area that will help drive growth for GSK to meet its future
outlooks.
Respiratory, Immunology & Inflammation
camlipixant (P2X3 receptor antagonist)
Camlipixant
(BLU-5937) is an investigational, highly selective oral P2X3
receptor antagonist, designed to target the hypersensitive nerves
that may be associated with refractory chronic cough (RCC).
Camlipixant is currently in development as a potential first-line
treatment of adult patients suffering from RCC. The CALM phase III
development programme to evaluate the efficacy and safety of
camlipixant for use in adults with RCC is ongoing.
Key
phase III trials for camlipixant:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
CALM-1
(refractory chronic cough)
NCT05599191
|
III
|
A
52-week, randomised, double-blind, placebo-controlled, parallel-arm
efficacy and safety trial with open-label extension of camlipixant
in adult participants with refractory chronic cough, including
unexplained chronic cough
|
Trial
start:
Q4
2022
|
Completed,
awaiting data analysis
|
|
CALM-2
(refractory chronic cough)
NCT05600777
|
III
|
A
24-week, randomised, double-blind, placebo-controlled, parallel-arm
efficacy and safety trial with open-label extension of camlipixant
in adult participants with refractory chronic cough, including
unexplained chronic cough
|
Trial
start:
Q1
2023
|
Recruiting
|
efimosfermin (FGF21 analog)
Efimosfermin
(GSK6519754) is an investigational, once-monthly subcutaneous
injection of a long-acting variant of FGF21, designed to regulate
key metabolic pathways to decrease liver fat, ameliorate liver
inflammation, and reverse liver fibrosis in patients with metabolic
dysfunction-associated steatohepatitis (MASH).
Efimosfermin
has advanced to phase III development following the start of the
ZENITH trials. These trials are investigating its efficacy and
safety in patients with moderate and advanced fibrosis (F2 to F3)
caused by MASH.
Key
phase III trials for efimosfermin:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
ZENITH-1
(metabolic dysfunction-associated steatohepatitis
NCT07221227
|
III
|
A phase
III, randomized, double-blind, placebo-controlled, 3-arm study to
investigate the safety and efficacy of efimosfermin alfa in
participants with biopsy-confirmed F2- or F3-stage metabolic
dysfunction-associated steatohepatitis (MASH)
|
Trial
start:
Q4
2025
|
Recruiting
|
|
ZENITH-2
(metabolic dysfunction-associated steatohepatitis)
NCT07221188
|
III
|
A phase
III, randomized, double-blind, placebo-controlled, 3-arm study to
investigate the safety and tolerability of efimosfermin alfa in
participants with known or suspected F2- or F3-stage metabolic
dysfunction-associated steatohepatitis (MASH)
|
Trial
start:
Q4
2025
|
Recruiting
|
Exdensur (depemokimab; ultra-long-acting
anti-IL5)
In Q4,
GSK announced the approval of Exdensur (depemokimab) by the US Food
and Drug Administration (FDA) in severe asthma with an eosinophilic
phenotype. In addition, Exdensur received marketing
authorisation from the UK’s Medicines and Healthcare products
Regulatory Agency (MHRA) and Japan’s Ministry of Health,
Labour and Welfare (MHLW) in severe asthma and chronic
rhinosinusitis with nasal polyps (CRSwNP). It also received a
positive Committee for Medicinal Products for Human Use (CHMP)
opinion in the EU for severe asthma and CRSwNP and it is currently
under regulatory review in other countries, including in China.
Submissions in other markets are expected to progress through the
year.
Exdensur is the first and only ultra-long-acting biologic to
address severe asthma and CRSwNP. It is engineered to have an
extended half-life and high binding affinity and potency for IL-5,
enabling twice-yearly dosing.
Exdensur is in late-stage development in a range of IL-5
mediated conditions including hypereosinophilic syndrome (HES) and
eosinophilic granulomatosis with polyangiitis (EGPA).
GSK has
also initiated the ENDURA-1 and ENDURA-2 phase III clinical trials
assessing the efficacy and safety of depemokimab as an add-on
therapy in patients with uncontrolled moderate to severe chronic
obstructive pulmonary disease (COPD) with type 2 inflammation. In
Q4, GSK initiated a further phase III trial, VIGILANT, to assess
early use of depemokimab in patients with COPD with type 2
inflammation who have experienced one exacerbation and are at high
risk for future exacerbations.
Key
phase III trials for depemokimab:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
SWIFT-1
(severe asthma)
NCT04719832
|
III
|
A
52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial
start:
Q1
2021
Data
reported:
Q2
2024
|
Completed;
primary endpoint met
|
|
SWIFT-2
(severe asthma)
NCT04718103
|
III
|
A
52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial
start:
Q1
2021
Data
reported:
Q2
2024
|
Completed;
primary endpoint met
|
Key
phase III trials for depemokimab continued:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
AGILE
(severe asthma)
NCT05243680
|
III
(exten-
sion)
|
A
52-week, open label extension phase of SWIFT-1 and SWIFT-2 to
assess the long-term safety and efficacy of depemokimab adjunctive
therapy in adult and adolescent participants with severe
uncontrolled asthma with an eosinophilic phenotype
|
Trial
start:
Q1
2022
Data
reported:
Q2
2025
|
Completed,
primary endpoint met
|
|
NIMBLE
(severe asthma)
NCT04718389
|
IIIb
|
A
52-week, randomised, double-blind, double-dummy, parallel group,
multi-centre, non-inferiority trial assessing exacerbation rate,
additional measures of asthma control and safety in adult and
adolescent severe asthmatic participants with an eosinophilic
phenotype treated with depemokimab compared with mepolizumab or
benralizumab
|
Trial
start:
Q1
2021
|
Completed,
awaiting data analysis
|
|
ANCHOR-1
(chronic rhinosinusitis with nasal polyps; CRSwNP)
NCT05274750
|
III
|
A
52-week randomised, double-blind, parallel group phase III study to
assess the efficacy and safety of 100 mg SC depemokimab in patients
with chronic rhinosinusitis with nasal polyps (CRSwNP)
|
Trial
start:
Q2
2022
Data
reported: Q3 2024
|
Completed,
coprimary endpoints met
|
|
ANCHOR-2
(CRSwNP)
NCT05281523
|
III
|
A
52-week randomised, double-blind, parallel group phase III study to
assess the efficacy and safety of 100 mg SC depemokimab in patients
with chronic rhinosinusitis with nasal polyps (CRSwNP)
|
Trial
start:
Q2
2022
Data
reported:
Q3
2024
|
Completed;
coprimary endpoints met
|
|
OCEAN
(eosinophilic granulomatosis with polyangiitis; EGPA)
NCT05263934
|
III
|
A
52-week, randomised, double-blind, double-dummy, parallel-group,
multi-centre, non-inferiority study to investigate the efficacy and
safety of depemokimab compared with mepolizumab in adults with
relapsing or refractory eosinophilic granulomatosis with
polyangiitis (EGPA) receiving standard of care therapy
|
Trial
start:
Q3
2022
|
Active,
not recruiting
|
|
DESTINY
(hyper-eosinophilic syndrome; HES)
NCT05334368
|
III
|
A
52-week, randomised, placebo-controlled, double-blind, parallel
group, multicentre trial of depemokimab in adults with uncontrolled
HES receiving standard of care therapy
|
Trial
start:
Q3
2022
|
Recruiting
|
|
ENDURA-1
(chronic obstructive pulmonary disease; COPD)
NCT06959095
|
III
|
A
randomised, double-blind, placebo- controlled, parallel-group,
multicenter study of the efficacy and safety of depemokimab in
adult participants with COPD with type 2 inflammation
|
Trial
start: Q2 2025
|
Recruiting
|
|
ENDURA-2
(COPD)
NCT06961214
|
III
|
A
randomised, double-blind, placebo- controlled, parallel-group,
multicenter study of the efficacy and safety of depemokimab in
adult participants with COPD with type 2 inflammation
|
Trial
start: Q2 2025
|
Recruiting
|
|
VIGILANT
(COPD)
NCT07177339
|
III
|
A
randomised, double-blind, parallel group, placebo-controlled study
of the efficacy and safety of early depemokimab initiation as
add-on treatment in COPD patients with type 2
inflammation
|
Trial
start: Q4 2025
|
Recruiting
|
Nucala (mepolizumab)
Nucala is a first in class anti-IL-5 biologic and the only
treatment approved in the US for use across five diseases with
underlying type 2 inflammation: severe asthma with an eosinophilic
phenotype, EGPA, HES, CRSwNP and COPD.
In Q4,
Nucala was approved in
China and the UK as an add-on maintenance treatment for adult
patients with inadequately controlled COPD characterised by raised
blood eosinophils. Nucala
also received a positive CHMP opinion for use in Europe in
uncontrolled patients with COPD characterised by raised blood
eosinophils, with a regulatory decision expected in Q1
2026.
Key
phase III trials for Nucala:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
MATINEE
(chronic obstructive pulmonary disease; COPD)
NCT04133909
|
III
|
A
multicentre randomised, double-blind, parallel-group,
placebo-controlled trial of mepolizumab 100 mg subcutaneously as
add-on treatment in participants with COPD experiencing frequent
exacerbations and characterised by eosinophil levels
|
Trial
start:
Q4
2019
Data
reported:
Q3
2024
|
Completed;
primary endpoint met
|
Oncology
Blenrep (belantamab
mafodotin)
Blenrep in combination is approved in 3L+ relapsed or
refractory multiple myeloma in the US based on the DREAMM-7 trial
and in the 2L+ setting based on both DREAMM-7 and DREAMM-8 in more
than a dozen markets including the EU, UK, Japan, Canada,
Switzerland, Brazil and Australia, with additional applications
under review globally.
GSK is
advancing the DREAMM (DRiving Excellence in Approaches to Multiple
Myeloma) clinical development programme to demonstrate Blenrep’s potential benefit in
earlier lines of treatment. This includes DREAMM-10, a phase III
trial in newly diagnosed transplant-ineligible patients, which
represent over 70% of patients starting multiple myeloma
therapy.
Key
phase III trials for Blenrep:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
DREAMM-7
(2L+ multiple myeloma; MM)
NCT04246047
|
III
|
A
multi-centre, open-label, randomised trial to evaluate the efficacy
and safety of the combination of belantamab mafodotin, bortezomib,
and dexamethasone (B-Vd) compared with the combination of
daratumumab, bortezomib and dexamethasone (D-Vd) in participants
with relapsed/refractory multiple myeloma
|
Trial
start:
Q2
2020
Primary
data reported:
Q4 2023
|
Active,
not recruiting; primary endpoint met
|
|
DREAMM-8
(2L+ MM)
NCT04484623
|
III
|
A
multi-centre, open-label, randomised trial to evaluate the efficacy
and safety of belantamab mafodotin in combination with pomalidomide
and dexamethasone (B-Pd) versus pomalidomide plus bortezomib and
dexamethasone (P-Vd) in participants with relapsed/refractory
multiple myeloma
|
Trial
start:
Q4
2020
Primary
data reported:
Q1
2024
|
Active,
not recruiting, primary endpoint met
|
|
DREAMM-10
(1L MM)
NCT06679101
|
III
|
A
multi-centre, open-label, randomised trial to evaluate the efficacy
and safety of belantamab mafodotin, lenalidomide and dexamethasone
(B-Rd) versus daratumumab, lenalidomide, and dexamethasone (D-Rd)
in participants with newly diagnosed multiple myeloma who are
ineligible for autologous stem cell transplantation
|
Trial
start:
Q4
2024
|
Recruiting
|
Jemperli (dostarlimab)
Jemperli remains the foundation of GSK’s
immuno-oncology-based research and development programme. It is the
only approved immuno-oncology-based plus CP treatment regimen to
demonstrate a statistically significant and clinically meaningful
overall survival benefit vs. CP alone for the first-line treatment
of adult patients with primary advanced or recurrent endometrial
cancer irrespective of biomarker status. Ongoing pivotal trials
include those in our AZUR programme (colon / rectal cancers), JADE
(head and neck cancer), and DOMENICA (supported-collaborative study
with ARCAGY-GINECO in endometrial cancer).
In
November 2025, the US FDA announced that it has granted a
Commissioner's National Priority Voucher to accelerate review of
the potential upcoming regulatory filing for dostarlimab for the
treatment of locally advanced dMMR/MSI-H rectal cancer. The current
standard of care for these patients is chemotherapy plus radiation
followed by surgery, which can be associated with significant
negative quality-of-life complications, highlighting the urgent
need for new options in the curative-intent setting.
Key
trials for Jemperli:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RUBY
(1L stage III or IV endometrial cancer)
NCT03981796
|
III
|
A
randomised, double-blind, multi-centre trial of dostarlimab plus
carboplatin-paclitaxel with and without niraparib maintenance
versus placebo plus carboplatin-paclitaxel in patients with
recurrent or primary advanced endometrial cancer
|
Trial
start:
Q3
2019
Part 1
data reported:
Q4
2022
Part 2
data reported:
Q4
2023
|
Active,
not recruiting; primary endpoints met
|
|
GARNET
(advanced solid tumours)
NCT02715284
|
I/II
|
A
multi-centre, open-label, first-in-human trial evaluating
dostarlimab in participants with advanced solid tumours who have
limited available treatment options
|
Trial
start:
Q1
2016
Primary
data reported:
Q1
2019
|
Active,
not recruiting
|
Key
trials for Jemperli continued:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
AZUR-1
(stage II/III rectal cancer)
NCT05723562
|
II
|
A
single-arm, open-label trial with dostarlimab monotherapy in
participants with untreated stage II/III dMMR/MSI-H locally
advanced rectal cancer
|
Trial
start:
Q1
2023
|
Active,
not recruiting
|
|
AZUR-2
(untreated perioperative T4N0 or stage III colon
cancer)
NCT05855200
|
III
|
An
open-label, randomised trial of perioperative dostarlimab
monotherapy versus standard of care in participants with untreated
T4N0 or stage III dMMR/MSI-H resectable colon cancer
|
Trial
start:
Q3
2023
|
Recruiting
|
|
JADE
(locally advanced unresected head and neck cancer)
NCT06256588
|
III
|
A
randomised, double-blind, study to evaluate dostarlimab versus
placebo as sequential therapy after chemoradiation in participants
with locally advanced unresected head and neck squamous cell
carcinoma
|
Trial
start:
Q1
2024
|
Recruiting
|
|
DOMENICA*
(relapsed or advanced dMMR endometrial cancer)
NCT05201547
*supported-collaborative
study with ARCAGY-GINECO
|
III
|
A
randomized, multicentre study to evaluate the efficacy and safety
of dostarlimab versus carboplatin-paclitaxel in patients with dMMR
relapsed or advanced endometrial cancer
|
Trial
start:
Q2
2022
|
Active,
not recruiting
|
Risvutatug rezetecan
GSK is
advancing its B7H3-targeted antibody-drug conjugate, risvutatug
rezetecan through the EMBOLD global development programme across a
range of solid tumours, including certain types of lung, prostate
and colorectal cancers.
In
December 2025, risvutatug rezetecan received orphan drug
designation (ODD) from the US FDA for the treatment of small-cell
lung cancer (SCLC). The ODD was supported by preliminary clinical
data showing durable responses in patients with extensive stage
SCLC (ES-SCLC) who were treated with risvutatug rezetecan in the
phase I ARTEMIS-001 clinical trial. It is the fifth regulatory
designation for risvutatug rezetecan. Previously, the EMA granted
risvutatug rezetecan ODD for pulmonary neuroendocrine carcinoma, a
category of cancer that includes SCLC and Priority Medicines
(PRIME) Designation for relapsed or refractory ES-SCLC. The US FDA
previously granted Breakthrough Therapy Designations for relapsed
or refractory ES-SCLC and relapsed or refractory
osteosarcoma.
Key
phase III trials for risvutatug rezetecan:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
EMBOLD-SCLC-301
NCT07099898
|
III
|
A
multicenter, randomized, open-label study of risvutatug rezetecan
compared with topotecan in participants with relapsed small cell
lung cancer
|
Trial
start:
Q3
2025
|
Recruiting
|
Zejula (niraparib)
GSK
continues to assess the potential of niraparib, currently approved
as Zejula as a maintenance
treatment for advanced ovarian cancer, in addressing other
challenging cancers. Niraparib monotherapy is being evaluated in
patients with newly diagnosed, MGMT unmethylated glioblastoma in
the phase III GLIOFOCUS trial sponsored by the Ivy Brain Tumor
Center and supported by GSK.
Key
phase III trials for Zejula:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
GLIOFOCUS
(Glioblastoma) – sponsored by the Ivy Brain Tumor Center and
supported by GSK
NCT06388733
|
III
|
An
open-label, randomised 2-arm study comparing the clinical efficacy
and safety of niraparib with temozolomide in adult participants
with newly diagnosed, MGMT unmethylated glioblastoma
|
Trial
start:
Q2
2024
|
Recruiting
|
HIV
As a
pioneer in long-acting injectables, ViiV Healthcare, majority owned
by GSK, is focused on the next-generation of HIV innovation with
integrase inhibitors (INSTIs), the gold standard for HIV regimens,
at the core. The HIV pipeline will continue to drive sustained
performance and the ongoing transition of the portfolio to
long-acting regimens.
In
2025, data from VOLITION, LATITUDE and CLARITY trials reinforced
ViiV’s leadership in long-acting HIV care, with consistently
superior effectiveness, safety and patient preference,
differentiating the portfolio and setting the pace for the
industry’s next chapter. The phase II registrational EXTEND
trial of cabotegravir four-monthly HIV prevention is progressing
with data expected in 2026. The phase III CUATRO trial exploring
cabotegravir + rilpivirine four-monthly HIV treatment is expected
to start in 2026.
Key HIV
trials:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
EXTEND
4M (HIV)
NCT06741397
|
II
|
Phase
IIb open label, single arm, repeat dose study to investigate the
safety, tolerability and pharmacokinetics (PK) of CAB ULA
administered intramuscularly every four months in participants at
risk of acquiring HIV-1.
|
Trial
start:
Q4
2024
|
Active,
not recruiting
|
|
EMBRACE
(HIV)
NCT05996471
|
IIb
|
The
study aims at evaluating the efficacy of VH3810109, dosed in
accordance with the dosing schedule as either intravenous (IV)
infusion or subcutaneous (SC) infusion with recombinant
hyaluronidase (rHuPH20), in combination with cabotegravir (CAB)
intramuscular (IM) dosed in accordance with the dosing schedule in
virologically suppressed, Antiretroviral therapy (ART)-experienced
adult participants living with HIV.
|
Trial
start: Q3 2023
|
Active,
not recruiting
|
Infectious Diseases
Arexvy (respiratory
syncytial virus vaccine, adjuvanted)
GSK
continues to progress the life-cycle management of Arexvy, its RSV vaccine for adults,
with potential expanded indications in new populations and
geographies.
In
January 2026, the European Commission issued approved the expanded
use of Arexvy in adults 18
years and older, following a positive Committee for Medicinal
Products for Human Use (CHMP) opinion issued in December 2025.The
EMA is also reviewing the vaccine for use in immunocompromised
adults aged 18 years and older with a decision expected in H1 2026.
In October 2025, the EMA approved an update to Arexvy’s EU label to allow
concomitant administration with mRNA COVID-19 vaccine. Regulatory
reviews are ongoing in the US and Japan to expand use of
Arexvy in adults aged 18-49
years of age at increased risk of RSV disease and in
immunocompromised adults aged 18 years and older.
Regulatory
reviews are also ongoing for registration of an additional
vial/pre-filled syringe (Vial/PFS) presentation of Arexvy in both the EU and the
US.
The
vaccine has now been approved for use in 69 markets
worldwide.
Key
trials for Arexvy:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RSV
OA=ADJ-004
(Adults
≥ 60 years old)
NCT04732871
|
III
|
A
randomised, open-label, multi-country trial to evaluate the
immunogenicity, safety, reactogenicity and persistence of a single
dose of the RSVPreF3 OA investigational vaccine and different
revaccination schedules in adults aged 60 years and
above
|
Trial
start:
Q1
2021
Primary
data reported:
Q2
2022
|
Active,
not recruiting; primary endpoint met
|
|
RSV
OA=ADJ-006
(ARESVI-006;
Adults ≥ 60 years old)
NCT04886596
|
III
|
A
randomised, placebo-controlled, observer-blind, multi-country trial
to demonstrate the efficacy of a single dose of GSK’s
RSVPreF3 OA investigational vaccine in adults aged 60 years and
above
|
Trial
start:
Q2
2021
Primary
data reported:
Q2
2022;
two
season data reported:
Q2
2023;
three
season data reported: Q3 2024
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-012
(Adults
aged 60 years and above)
NCT06534892
|
IIIb
|
An
extension and crossover vaccination study on the immune response
and safety of a vaccine against Respiratory Syncytial Virus given
to adults 60 years of age and above who participated in RSV
OA=ADJ-006 study
|
Trial
start:
Q3
2024
|
Recruiting
|
|
RSV-OA=ADJ-013
(Adults
aged 50 years and above)
NCT06374394
|
III
|
An
open-label, randomized, controlled study to evaluate the immune
response, safety and reactogenicity of RSVPreF3 OA investigational
vaccine when co-administered with a COVID-19 mRNA
vaccine
|
Trial
start:
Q2
2024
Primary
data reported: Q3 2025
|
Complete
|
Key trials for Arexvy continued:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RSV
OA=ADJ-019
(Adults
≥ 60 years old)
NCT05879107
|
III
|
An
open-label, randomised, controlled, multi-country trial to evaluate
the immune response, safety and reactogenicity of RSVPreF3 OA
investigational vaccine when co-administered with PCV20 in adults
aged 60 years and older
|
Trial
start:
Q2
2023
Primary
data reported: Q1 2025
|
Complete;
primary endpoint met
|
|
RSV-OA=ADJ-020
(Adults
aged >=50 years of age)
NCT05966090
|
III
|
A study
on the safety and immune response of investigational RSV OA vaccine
in combination with Herpes
zoster vaccine in healthy adults
|
Trial
start:
Q3
2023
Primary
data reported: Q3 2024
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-023
(Immunocompromised
adults 50-59 years)
NCT05921903
|
IIb
|
A
randomised, controlled, open-label trial to evaluate the immune
response and safety of the RSVPreF3 OA investigational vaccine in
adults (≥50 years of age) when administered to lung and renal
transplant recipients comparing one versus two doses and compared
to healthy controls (≥50 years of age) receiving one
dose
|
Trial
start:
Q3
2023
Primary
data reported:
Q4
2024
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-025
(Adults,
18-49 years of age, at increased risk for RSV disease and older
adult participants, >=60 YOA)
NCT06389487
|
IIIb
|
An
open-label study to evaluate the non-inferiority of the immune
response and to evaluate the safety of the RSVPreF3 OA
investigational vaccine in adults 18-49 years of age at increased
risk for Respiratory Syncytial Virus disease, compared to older
adults >=60 years of age
|
Trial
start:
Q2
2024
Primary
data reported:
Q3
2024
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-031
(Immunocompromised
adults >=18 years of age)
NCT07092865
|
II
|
A
non-randomized, controlled, open-label, extension study to evaluate
the persistence of immune response of the adjuvanted RSVPreF3
vaccine and the safety and immunogenicity following revaccination
in lung and kidney transplant recipients (>=18 years of
age)
|
Trial
start: Q3 2025
|
Recruiting
|
|
RSV
OA=ADJ-021
(Adults
aged 60 years and above)
NCT06551181
|
III
|
A study
on the immune response, safety and the occurrence of Respiratory
Syncytial Virus (RSV)-associated respiratory tract illness after
administration of RSV OA vaccine in adults 60 years and older in
China and other countries
|
Trial
start:
Q3
2024
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-028
(Adults
18 to 59 years of age at increased risk for RSV
Disease)
NCT07220109
|
III
|
A
randomized, controlled, observer blind, immuno-bridging study to
evaluate immunogenicity, reactogenicity and safety of a single dose
of the RSVPreF3 OA investigational vaccine in Chinese adults 18-59
years of age at increased risk of RSV Disease
|
Trial
start:
Q4
2025
|
Recruiting
|
|
RSV
OA=ADJ-024
(Adults
≥60 years of age and adults 50 59 years of age at increased
risk for RSV disease)
NCT06614725
|
III
|
A
randomized, placebo-controlled, observer-blind study in India to
evaluate immune response, reactogenicity and safety of the RSVPreF3
OA investigational vaccine when administered to older adults
≥60 years of age and adults 50 59 years of age at increased
risk of RSV disease.
|
Trial
start:
Q3
2024
|
Complete
|
bepirovirsen (HBV ASO)
Bepirovirsen
is a triple-action antisense oligonucleotide with the potential to
be a first in class new treatment option for people with chronic
hepatitis B (CHB). In January 2026, GSK announced positive results
from its two pivotal phase III trials, B-Well 1 and B-Well 2. The
trials met their primary endpoints with bepirovirsen demonstrating
a statistically significant and clinically meaningful functional
cure rate. Functional cure rates were significantly higher with
bepirovirsen plus standard of care compared with standard of care
alone. Global regulatory submissions are planned from Q1 2026. If
approved, bepirovirsen has the potential to become the first
finite, six-month therapeutic option for CHB and to serve as a
backbone for future sequential treatment strategies.
Bepirovirsen
has been recognised by global regulatory authorities for its
innovation and potential to address significant unmet need in
hepatitis B, with Fast Track designation from the US FDA,
Breakthrough Therapy designation in China and SENKU designation in
Japan.
To
further expand development of novel sequential regimens, GSK
entered an agreement for an exclusive worldwide license to develop
and commercialise daplusiran/tomligisiran (GSK5637608, formerly
JNJ-3989), an investigational hepatitis B virus-targeted small
interfering ribonucleic acid (siRNA) therapeutic. This agreement
provides an opportunity to investigate a novel sequential regimen
to pursue functional cure in an even broader patient population
with bepirovirsen. Phase IIb trials for this sequential therapy
started in Q4 2024.
Key
trials for bepirovirsen:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
B-Well
1 bepirovirsen in nucleos(t)ide treated patients (chronic hepatitis
B)
NCT05630807
|
III
|
A
multi-centre, randomised, double-blind, placebo-controlled trial to
confirm the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial
Start:
Q1
2023
|
Completed;
primary endpoint met
|
|
B-Well
2 bepirovirsen in nucleos(t)ide treated patients (chronic hepatitis
B)
NCT05630820
|
III
|
A
multi-centre, randomised, double-blind, placebo-controlled trial to
confirm the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial
Start:
Q1
2023
|
Completed;
primary endpoint met
|
|
B-United
bepirovirsen sequential therapy with daplusiran/tomligisiran in
nucleos(t)ide treated patients (chronic hepatitis B)
NCT06537414
|
IIb
|
A
multi-centre, randomized, partially placebo-controlled,
double-blind study to investigate the safety and efficacy of
sequential therapy with daplusiran/tomligisiran followed by
bepirovirsen in participants with chronic hepatitis B virus on
background nucleos(t)ide analogue therapy
|
Trial
start:
Q4
2024
|
Active,
not recruiting
|
|
B-Sure
Long-term Follow-up Study to Evaluate Durability of Treatment
Response in Previous Bepirovirsen Study Participants
NCT04954859
|
II
|
A
global multi-center, long-term follow-up study to assess durability
of efficacy, as measured by maintenance of treatment response from
the parent study, in participants who participated in a previous
bepirovirsen study and achieved a complete or partial response.
Eligible participants will be enrolled in this study after
completing the end of study (EoS) visit in one of five parent
bepirovirsen studies.
|
Trial
Start: Q1 2021
|
Recruiting
|
Blujepa (gepotidacin; bacterial topoisomerase
inhibitor)
Blujepa is a first-in-class oral antibiotic with a novel
mechanism of action that is part of GSK’s infectious diseases
portfolio. It is approved in the US and the UK for the treatment of
female adults and paediatric patients (≥12 years, ≥40
kg) with uncomplicated urinary tract infections (uUTIs). Regulatory
review is ongoing in Australia. In December 2025, the US FDA
approved a supplemental New Drug Application for gepotidacin as an
oral option for the treatment of uncomplicated urogenital
gonorrhoea in patients 12 years of age and older (weighing >45
kg) with limited or no alternative.
Key
phase III trials for gepotidacin:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
EAGLE-1
(uncomplicated urogenital gonorrhoea)
NCT04010539
|
III
|
A
randomised, multi-centre, open-label trial in adolescent and adult
participants comparing the efficacy and safety of gepotidacin to
ceftriaxone plus azithromycin in the treatment of uncomplicated
urogenital gonorrhoea caused by Neisseria gonorrhoeae
|
Trial
start:
Q4
2019
Data
reported:
Q1
2024
|
Complete;
primary
endpoint met
|
|
EAGLE-2
(females with uUTI / acute cystitis)
NCT04020341
|
III
|
A
randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial
start:
Q4
2019
Data
reported:
Q2
2023
|
Complete;
primary endpoint met
|
|
EAGLE-3
(females with uUTI / acute cystitis)
NCT04187144
|
III
|
A
randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial
start:
Q2
2020
Data
reported:
Q2
2023
|
Complete;
primary endpoint met
|
tebipenem HBr
GSK has
an exclusive licence agreement with Spero Therapeutics, Inc. for
the development of tebipenem HBr (oral carbapenem antibiotic). In
May 2025, the phase III PIVOT-PO trial evaluating tebipenem HBr as
oral treatment for complicated urinary tract infections (cUTIs),
including pyelonephritis, was stopped early for efficacy following
a recommendation from an Independent Data Monitoring
Committee.
Following
positive phase III data from the PIVOT-PO trial, GSK has filed a
regulatory submission in the US which has been accepted by the FDA.
The PDUFA date has been set as 18 June 2026. If approved, tebipenem
HBr could be the first oral carbapenem antibiotic for patients in
the US who suffer from cUTIs, adding to GSK’s innovative
anti-infectives portfolio and helping address the challenges of
antimicrobial resistance (AMR).
Key
phase III trials for tebipenem HBr:
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
PIVOT-PO
(complicated urinary tract infections)
NCT06059846
|
III
|
A
randomised, double-blind, double-dummy, multi-centre study to
assess the efficacy and safety of orally administered tebipenem
pivoxil hydrobromide compared to intravenously administered
imipenem-cilastatin in patients with complicated urinary tract
infection (cUTI) or acute pyelonephritis (AP)
|
Trial
start:
Q4
2023
Data
reported:
Q2
2025
|
Complete;
primary
endpoint met
|
Reporting
definitions
CAGR (Compound annual growth rate)
CAGR is
defined as the compound annual growth rate and shows the annualised
average rate for growth in sales and core operating profit between
2021 to 2026, assuming growth takes place at an exponentially
compounded rate during those years.
CER and AER growth
In
order to illustrate underlying performance, it is the Group’s
practice to discuss its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates used to determine the results of overseas companies in
Sterling had remained unchanged from those used in the comparative
period. CER% represents growth at constant exchange rates. For
those countries which qualify as hyperinflationary as defined by
the criteria set out in IAS 29 ‘Financial Reporting in
Hyperinflationary Economies’ (Argentina and Turkey) CER
growth is adjusted using a more appropriate exchange rate where the
impact is significant, reflecting depreciation of their respective
currencies in order to provide comparability and not to distort CER
growth rates.
AER%
represents growth at actual exchange rates.
Core Earnings per share
Unless
otherwise stated, Core earnings per share refers to Core basic
earnings per share.
Core Operating Margin
Core
Operating margin is Core operating profit divided by
turnover.
Free cash flow
Free
cash flow is defined as the net cash inflow/outflow from operating
activities less capital expenditure on property, plant and
equipment and intangible assets, contingent consideration payments,
net finance costs, and dividends paid to non-controlling interests,
contributions from non-controlling interests plus proceeds from the
sale of property, plant and equipment and intangible assets, and
dividends received from joint ventures and associates. The measure
is used by management as it is considered an indicator of net cash
generated from business activities (excluding any cash flows
arising from equity investments, business acquisitions or disposals
and changes in the level of borrowing) available to pay
shareholders dividends and to fund strategic plans. Free cash flow
growth is calculated on a reported basis. A reconciliation of net
cash inflow from operations to free cash flow from operations is
set out on page 42.
Free cash flow conversion
Free
cash flow conversion is free cash flow from operations as a
percentage of profit attributable to shareholders.
General Medicines
General
Medicines are usually prescribed in the primary care or community
settings by general healthcare practitioners. For GSK, this
includes medicines for inhaled respiratory, dermatology,
antibiotics and other diseases.
Non-controlling interest
Non-controlling
interest is the equity in a subsidiary not attributable, directly
or indirectly, to a parent.
Percentage points
Percentage
points of growth which is abbreviated to ppts.
RAR (Returns and Rebates)
GSK
sells to customers both commercial and government mandated
contracts with reimbursement arrangements that include rebates,
chargebacks and a right of return for certain pharmaceutical
products principally in the US. Revenue recognition reflects
gross-to-net sales adjustments as a result. These adjustments are
known as the RAR accruals and are a source of significant
estimation uncertainty and fluctuation which can have a material
impact on reported revenue from one accounting period to the
next.
Risk adjusted sales
Pipeline
risk-adjusted sales are based on the latest internal estimate of
the probability of technical and regulatory success for each asset
in development.
Specialty Medicines
Specialty
Medicines are typically prescription medicines used to treat
complex or rare chronic conditions. For GSK, this comprises
medicines for infectious diseases, HIV, Respiratory, Immunology
& Inflammation, and Oncology.
Total Net debt
Net
debt is defined as total borrowings less cash, cash equivalents,
liquid investments, and short-term loans to third parties that are
subject to an insignificant risk of change in value. The measure is
used by management as it is considered a good indicator of GSK's
ability to meet its financial commitments and the strength of its
balance sheet (including those classified as assets held for sale
and liabilities relating to assets held for sale).
Total Net debt/Core EBITDA ratio
Core
EBITDA is defined as Total operating profit excluding adjusting
items and core depreciation and amortisation (as described on page
43) and includes the share of core after tax profit/(loss) of
associates and joint ventures. Core depreciation is total
depreciation less depreciation arising as part of major
restructuring and is disclosed as part of adjusting items. Core
amortisation arises from computer software and internally
capitalised R&D development costs. Total Net debt is defined
above. The ratio is Total Net debt expressed as a multiple of Core
EBITDA which demonstrates a key leverage metric which assesses the
strength of the balance sheet.
Total and Core results
Total
reported results represent the Group’s overall performance.
GSK uses a number of non-IFRS measures to report the performance of
its business. Core results and other non-IFRS measures may be
considered in addition to, but not as a substitute for or superior
to, information presented in accordance with IFRS. Core results are
defined on page 18 and other non-IFRS measures are defined in pages
53 and 54.
Total Operating Margin
Total
Operating margin is Total operating profit divided by
turnover.
Total Earnings per share
Unless
otherwise stated, Total earnings per share refers to Total basic
earnings per share.
Working capital
Working
capital represents inventory and trade receivables less trade
payables.
Brand names and partner acknowledgements: brand names appearing in
italics throughout this document are trademarks of GSK or
associated companies or used under licence by the
Group.
Guidance and Outlooks, assumptions
and cautionary statements
2026 Guidance
GSK
expects its turnover to increase between 3 to 5 per cent and Core
operating profit to increase between 7 to 9 per cent. Core earnings
per share is also expected to increase between 7 to 9 per cent. GSK
provides its full-year 2026 guidance at constant exchange rates
(CER).
The
Group has made planning assumptions that we expect turnover for
Specialty Medicines to increase by a low double-digit per cent,
Vaccines to decline by a low-single digit per cent to stable, and
General Medicines to decline by a low-single digit per cent to
stable.
2021-2026 and 2031 Outlooks
In
February 2025 GSK set out improved outlooks for 2031 which are
detailed in the 2024 full year and fourth quarter results on
gsk.com(1).
Assumptions and basis of preparation related to 2026 Guidance,
2021-26 and 2031 Outlooks
In
outlining the guidance for 2026, and outlooks for the period
2021-26 and for 2031, the Group has made certain assumptions about
the macro-economic environment, the healthcare sector (including
regarding existing and possible additional governmental legislative
and regulatory reform), the different markets and competitive
landscape in which the Group operates and the delivery of revenues
and financial benefits from its current portfolio, its development
pipeline and restructuring programmes. As previously announced, on
19 December 2025 GSK entered into an agreement with the US
Administration to lower the cost of prescription medicines for
American patients. The agreement entered into covers both GSK and
ViiV Healthcare and, assuming expected implementation, excludes
both companies from s232 tariffs for 3 years. Detailed terms of the
agreement remain confidential. Our full year guidance is inclusive
of the expected impact of the agreement.
2026 Guidance
These
planning assumptions as well as operating profit and earnings per
share guidance and dividend expectations assume no material
interruptions to supply of the Group’s products, no material
mergers, acquisitions or disposals, no material litigation or
investigation costs for the Company (save for those that are
already recognised or for which provisions have been made) and no
change in the Group’s shareholdings in ViiV Healthcare. The
assumptions also assume no material changes in the healthcare
environment or unexpected significant changes in pricing or trade
policies, including tariffs (except as noted above), as a result of
government or competitor action. The 2026 guidance factors in all
divestments and product exits announced to date.
2021-26 and 2031 Outlooks
The
assumptions for GSK’s revenue, Core operating profit, Core
operating margin and cash flow outlooks, 2031 revenue outlook and
margin expectations through dolutegravir loss of exclusivity assume
the delivery of revenues and financial benefits from its current
and development pipeline portfolio of medicines and vaccines (which
have been assessed for this purpose on a risk-adjusted basis, as
described further below); regulatory approvals of the pipeline
portfolio of medicines and vaccines that underlie these
expectations (which have also been assessed for this purpose on a
risk-adjusted basis, as described further below); no material
interruptions to supply of the Group’s products; successful
delivery of the ongoing and planned integration and restructuring
plans; no material mergers, acquisitions or disposals or other
material business development transactions; no material litigation
or investigation costs for the Company (save for those that are
already recognised or for which provisions have been made); and no
change in the Group's shareholdings in ViiV Healthcare. GSK assumes
no premature loss of exclusivity for key products over the
period.
The
assumptions for GSK’s revenue, Core operating profit, Core
operating margin and cash flow outlooks, 2031 revenue outlook and
margin expectations through dolutegravir loss of exclusivity also
factor in all divestments and product exits announced to date as
well as material costs for investment in new product launches and
R&D. Risk-adjusted sales includes sales for potential planned
launches which are risk-adjusted based on the latest internal
estimate of the probability of technical and regulatory success for
each asset in development.
Notwithstanding
our guidance, outlooks and expectations, there is still uncertainty
as to whether our assumptions, guidance, outlooks and expectations
will be achieved.
All
outlook statements are given on a constant currency basis and use
2025 average exchange rates as a base (£1/$1.31,
£1/€1.17, £1/Yen 198).
(1)
https://www.gsk.com/media/11776/fy-2024-results-announcement.pdf
Assumptions and cautionary statement regarding forward-looking
statements
The
Group’s management believes that the assumptions outlined
above are reasonable, and that the guidance, outlooks, and
expectations described in this report are achievable based on those
assumptions. However, given the forward-looking nature of these
guidance, outlooks, and expectations, they are subject to greater
uncertainty, including potential material impacts if the above
assumptions are not realised, and other material impacts related to
foreign exchange fluctuations, macro-economic activity, the impact
of outbreaks, epidemics or pandemics, changes in legislation,
regulation, government actions and policies, including the impact
of any potential tariffs or other restrictive trade policies on the
Group's products, or intellectual property protection, product
development and approvals, actions by our competitors, and other
risks inherent to the industries in which we operate.
This
document contains statements that are, or may be deemed to be,
“forward-looking statements”. Forward-looking
statements give the Group’s current expectations or forecasts
of future events. An investor can identify these statements by the
fact that they do not relate strictly to historical or current
facts. They use words such as ‘anticipate’,
‘estimate’, ‘expect’, ‘intend’,
‘will’, ‘project’, ‘plan’,
‘believe’, ‘target’, ‘outlook’,
‘aim’, ‘ambition’, ‘could’,
‘goal’, ‘may’, ‘seek’,
‘should’ and other words and terms of similar meaning
in connection with any discussion of future operating or financial
performance. In particular, these include statements relating to
future actions, prospective products or product approvals, future
performance or results of current and anticipated products, sales
efforts, expenses, the outcome of contingencies such as legal
proceedings, dividend payments and financial results. Other than in
accordance with its legal or regulatory obligations (including
under the Market Abuse Regulation, the UK Listing Rules and the
Disclosure Guidance and Transparency Rules of the Financial Conduct
Authority), the Group undertakes no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise. The reader should, however, consult any
additional disclosures that the Group may make in any documents
which it publishes and/or files with the SEC. All readers, wherever
located, should take note of these disclosures. Accordingly, no
assurance can be given that any particular expectation will be met
and readers are cautioned not to place undue reliance on the
forward-looking statements.
All
guidance, outlooks and expectations should be read together with
the guidance and outlooks, assumptions and cautionary statements in
this full year and Q4 2025 earnings release and in the Group's 2024
Annual Report on Form 20-F.
Forward-looking
statements are subject to assumptions, inherent risks and
uncertainties, many of which relate to factors that are beyond the
Group’s control or precise estimate. The Group cautions
investors that a number of important factors, including those in
this document, could cause actual results to differ materially from
those expressed or implied in any forward-looking statement. Such
factors include, but are not limited to, those discussed under
‘Risk Factors’ in the Group’s Annual Report on
Form 20-F for 2024. Any forward-looking statements made by or on
behalf of the Group speak only as of the date they are made and are
based upon the knowledge and information available to the Directors
on the date of this report.
|
|
|
Glossary
|
|
|
|
|
Terms used in the Announcement
|
Brief description
|
|
1L
|
First
line
|
|
2L
|
Second
line
|
|
ACIP
|
Advisory
Committee on Immunization Practices
|
|
ADC
|
Antibody-drug-conjugates
|
|
ADP
|
Adenosine
diphosphate
|
|
AMP
|
Average
manufacturer price
|
|
ASO
|
Antisense
oligonucleotide
|
|
AS03
|
Adjuvant
system 03
|
|
Bnab
|
Broadly
neutralising antibody
|
|
CCL
|
Contingent
consideration liability
|
|
CDC
|
Centre
for Disease Control and Prevention
|
|
CHMP
|
Committee
for Medicinal Products for Human Use
|
|
CMS
|
Centre
for Medicare & Medicaid Services
|
|
COPD
|
Chronic
obstructive pulmonary disease
|
|
CROI
|
Conference
on Retroviruses and Opportunistic Infections
|
|
CRSwNP
|
Chronic
rhinosinusitis with nasal polyps
|
|
cUTIs
|
complicated
urinary tract infections
|
|
dMMR
|
Deficient
mismatch repair
|
|
DTG
|
Dolutegravir
|
|
EGPA
|
Eosinophilic
granulomatosis with polyangiitis
|
|
ES
|
Extensive
stage
|
|
ESOP
|
Employee
share ownership plan
|
|
GIST
|
Gastrointestinal
stromal tumours
|
|
HBV
|
Hepatitis
B virus
|
|
HES
|
Hypereosinophilic
syndrome
|
|
IBATi
|
Ileal
bile acid transporter inhibitor
|
|
Insti
|
Integrase
nuclear strand transfer inhibitors
|
|
IRA
|
Inflation
Reduction Act
|
|
JAK
|
Janus
kinase inhibitor
|
|
JAK1/JAK2
and ACVR1
|
once
a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1)
inhibitor
|
|
LA
|
Long
acting includes Cabenuva
and Apretude
|
|
MAPS
|
Multi
antigen presenting system
|
|
MASH
|
Metabolic
dysfunction-associated steatohepatitis
|
|
MDS
|
Myelodysplastic
Syndromes
|
|
MGMT
glioblastoma
|
methylated
DNA protein cysteine methyltransferase
|
|
MMR/V
|
Measles,
mumps, rubella and varicella
|
|
mo-rez
|
mocertatug
rezetecan
|
|
mRNA
|
messenger
ribonucleic acid
|
|
MSI-H
|
Microsatellite
Instability-High
|
|
OA
|
Older
adults
|
|
ODAC
|
Oncologic
Drugs Advisory Committee
|
|
OECD
|
Organisation
for Economic Co-operation and Development
|
|
Oral
2DR
|
Oral 2
drug regimen includes Dovato and Juluca
|
|
PARP
|
a Poly
ADP ribose polymerase
|
|
PBC
|
Primary
biliary cholangitis
|
|
PD-1
|
a
programmed death receptor-1 blocking antibody
|
|
PDUFA
|
Prescription
Drug User Fee Act
|
|
PK
|
Pharmacokinetics
|
|
ppts
|
percentage
points
|
|
PrEP
|
pre-exposure
prophylaxis
|
|
PYS
|
Peak
year sales
|
|
Q4M
|
every 4
months
|
|
Q6M
|
every 6
months
|
|
RCC
|
Refractory
chronic cough
|
|
ris-rez
|
risvutatug
rezetecan
|
|
RNS
|
Regulatory
news service
|
|
RSV
|
Respiratory
syncytial virus
|
|
SCLC
|
small
cell lung cancer
|
|
SITT
|
Single
inhaler triple therapy
|
|
SLD
|
Steatotic
liver disease
|
|
TIGIT
|
T cell
immunoreceptor with Ig and ITIM domains
|
|
TIM3
|
T-cell
membrane protein-3
|
|
TSLP
|
Long-acting
anti-thymic stromal lymphopoietin monoclonal
|
|
ULA
|
Ultra
long acting
|
|
uUTIs
|
uncomplicated
urinary tract infections
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
4, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
|
|